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ABSTRACT 
 
AIMS & OBJECTIVE: To assess and evaluate the effects of clary sage oil in 
Premenstrual syndrome. 
BACKGROUND: Premenstrual syndrome (PMS) is a condition that presents with 
distressing physical, behavioral, and psychological symptoms, in the absence of 
organic or underlying psychiatric disease, which regularly recurs during the luteal 
phase of each menstrual cycle, and which disappears or significantly regresses by the 
end of menstruation. It has been estimated from retrospective community surveys that 
nearly 90% of women have experienced at least some symptoms attributed to the 
premenstrual phase of menstrual cycle during their life. 
Aromatherapy is the practice of therapeutic use of essential plant-based oils. Essential 
oils and aromatherapy have been used in the care of women for centuries. Clary sage 
is a gift to the female and has a rejuvenating effect on the endocrine system and 
balances the pituitary and is specifically indicated in treating PMS. In aromatherapy, 
there are limited studies on Premenstrual syndrome. Moreover most papers are based 
on other aroma oils. 
DESIGN AND METHOD: 60 subjects were screened using Premenstrual Syndrome 
Screening Tool and randomized using convenient sampling method and into Study 
group (N = 30) and Placebo-control group (N= 30) on 1:1 ratio. The Subjects of Study 
group and Placebo-control group received their respective treatment three days a week 
for three months. Data was collected before and after 3 months of treatment using 
Premenstrual Syndrome Scale. 
RESULTS: The results show a high level of statistical and clinical significance and 
highly favours the intervention group in the reduction of all 3 components of the PMSS 
when compared to the placebo-controlled group. 
CONCLUSION: This trial suggested that Clary sage oil helps in reducing the 
physiological, psychological and behavioural symptoms of Premenstrual syndrome. 
KEY WORDS: Pre-menstrual syndrome, Clary sage, Aromatherapy, Premenstrual 
Syndrome Screening tool, Premenstrual Syndrome Scale. 
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1.INTRODUCTION 
Premenstrual syndrome (PMS) is a condition that presents with distressing 
physical, behavioral, and psychological symptoms, in the absence of organic or 
underlying psychiatric disease, which regularly recurs during the luteal phase of 
each menstrual cycle, and which disappears or significantly regresses by the end 
of menstruation[1].Although mild symptoms occur in approximately 75% of 
women of reproductive age[2],40% of women are reported to suffer from 
clinically significant PMS[3] 
The prevalence of PMS has been reported in 20-32% of premenopausal [4]and 
30%-40% of the reproductive female population globally [5]. The prevalence of 
PMS is reported to be 67% in India [6]. Women with PMS usually complain of 
somatic symptoms, such as food cravings, mastalgia, bloating, headache, lack of 
energy, abdominal discomfort and pain, and weight gain. Frequently reported 
affective changes include depression, angry outbursts, crying spells, anxiety, 
irritability, and feelings of being unable to cope [1]. 
The exact etiology of PMS is unknown, but it may be related to hormone 
variations. Some theories state that PMS is not caused by abnormal concentration 
of gonadal steroids but more likely by variations in levels of the sex hormones. 
The differences between women with and without PMS may also be explained by 
increased sensitivity to variations in levels of sex hormones[7].Moreover, some 
studies showed that the onset and course of PMS are related to stress[8].The 
variations in hormone levels across the menstrual cycle cause an increase in 
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negative emotions in women and can influence mood regulation and sensitivity 
to stress[9,10]. Specifically, women have stronger responses to stressors before 
the menstruation or in the luteal phase, which may increase the risk for negative 
emotions or moods, suggesting stress may strengthen PMS symptoms [11]. 
The pathophysiology of PMS or PMDD have not been established and 
hypotheses included hormone imbalances, sodium retention, nutritional 
deﬁciencies, abnormal neurotransmitter responses to normal ovarian function and 
abnormal hypothalamic pituitary-adrenal axis function [12,13]. 
 PMS symptoms, even though mild to moderate in intensity, might adversely 
affect and influence daily activities and work productivity [14]. It is more 
pronounced in cases of working females. Most of the studies done on this subject 
worldwide focus on women in general population or a specific subset of working 
females [15]. 
1.1 Background: 
Numerous treatments have been proposed over the past sixty years, and 
although some have been successful, each has adverse effects which may well 
outweigh their benefits [16]. O'Brien [17] stated that the proposed treatments 
were 
“either ineffective or that the high placebo effect in premenstrual 
syndrome leads to over optimistic conclusions being drawn”. 
Many doctors do not believe there is such condition as PMS and, consequently, 
fail to recognize and treat it. Of 482 women who called the National Association 
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for Premenstrual Syndrome (NAPS) helpline last year, 42% said that their GPs 
were unsympathetic or did not seem to know much about PMS[18]. Its 
recognition is a twentieth century event, reflecting changes in our social structure 
and lifestyle. In the past the time between puberty and the menopause was filled 
with many pregnancies when PMS disappears. Each was followed by the 
cessation of ovulation caused by prolonged breastfeeding. Nowadays with fewer 
pregnancies the effects of the menstrual cycle are more apparent [19]. 
1.2 Prevalence: 
The true prevalence of PMS is difficult to determine because of self-
treatment, differences in availability and access to health services, definition & 
diagnostic criteria and cultural practices [20]. It has been estimated from 
retrospective community surveys that nearly 90% of women have experienced at 
least one premenstrual syndrome. Epidemiological surveys have estimated that as 
many as 75% of women in their reproductive age experience some symptoms 
attributed to the premenstrual phase of menstrual cycle during their life [21,22].It 
is also estimated that up to 85% of premenopausal women experience at least one 
premenstrual symptom and 15-20% meet clinical criteria for premenstrual 
syndrome (PMS) [23]. Among the gynecological problems, menstrual problems 
are said to be the major ones especially among adolescent females [24]. 
 1.3 Clinical features: 
Premenstrual symptoms reappear monthly and last for an average of 6 days 
per month for the majority of the reproductive years. It has been calculated that 
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affected women experience almost 3000 days of severe symptoms during the 
reproductive years [25]. The significant appearance of these symptoms starts 
from the teen years and worsen through the process of ageing [25]. More than 
200 symptoms of PMS have been described in literature, ranging from mild 
symptoms to those severe enough to interfere with normal activities [26].  
The most important somatic symptoms are feeling overwhelmed, food craving, 
insomnia or hypersomnia, headache, pelvic pain and discomfort, breast 
tenderness, joint pain, bloating ; and the most common and distressing affective 
symptoms are irritability, anxiety, depression, mood swinging, hostility, poor 
concentration, confusion, social withdrawal and interpersonal conflicts[27,28].Of 
these, six symptoms identified as core symptoms suggesting that clinical 
diagnosis of PMS can be developed around a core symptom group. The identified 
core symptoms are: anxiety/tension, mood swings, aches, appetite/food cravings, 
cramps, and decreased interest in activities [29].  
1.4 Pathophysiology of PMS: 
In evolutionary terms,[30] luteal mood changes could be remnants of the 
oestrogen cycle-related fluctuations in behaviour shown by lower species with 
the original purpose of promoting reproduction: sexual receptivity being 
increased and aggression decreased when oestrogen is high before 
ovulation[31,32]. 
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1.4.1 Role of Progesterone: 
Since the 1980s, the factor responsible for provoking symptoms of PMS 
has been attributed to the progesterone produced by the corpus luteum [33]. 
During anovulatory cycles, when a corpus luteum fails to form, the symptoms of 
PMS are not observed [34]. Premenarchal girls, postmenopausal women and 
those who have undergone bilateral oophorectomy also do not experience PMS. 
Nevertheless, the role of progesterone in triggering adverse symptomatology is 
not straightforward. For example, PMS symptoms are absent during pregnancy, 
in spite of high progesterone and estrogen concentrations. It is unclear how long 
after conception the typical PMS symptoms that are linked to the luteal phase 
hormonal complement will diminish. Administration of exogenous progesterone 
or a progestogen can also engender symptoms akin to PMS. Postmenopausal 
women receiving hormonal therapy consisting of both estrogen and a 
progestogen may experience PMS-like complaints consisting of negative mood 
and somatic symptoms. These undesirable effects were investigated and have 
been attributed to the progestogen [35]. In addition, PMS-like symptoms often 
persist even after anovulation has been induced with a hormonal contraceptive, 
and again it has been hypothesized that the exogenous progestogens are 
responsible, although the dose of estrogen may also be relevant. There are a 
number of studies suggesting oral contraceptive pills (OCPs), regardless of the 
elimination of ovulation, can be associated with ‘PMS-like’ negative affective 
and physical symptoms such as irritability, depression, anxiety, bloating, fatigue 
and breast tenderness in a subset of women [36]. Although compelling evidence 
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points to the role of progesterone in the pathophysiology of PMDs, it appears that 
the classical progesterone receptor is not involved in this process. This 
observation is supported by lack of reduction in physical or behavioural 
manifestation of PMS with administration of the progesterone receptor 
antagonist, mifepristone [37]. In addition, numerous studies have been unable to 
provide evidence for progesterone excess or deﬁciency in the aetiology of PMDs. 
In multiple studies, measurement of serum progesterone in women with PMS 
compared with controls failed to show any signiﬁcant differences [33]. Finally, a 
series of randomized double-blinded placebo-controlled trials (RCTs) failed to 
show efﬁcacy of progesterone supplementation [38]. Other reproductive 
hormones, estradiol, testosterone, the adrenal hormones cortisol and 
dehydroepiandrosterone sulphate and the pituitary and thyroid hormones 
including prolactin and thyroxin also fail to distinguish women with PMDs from 
controls. Although in one study, more severe symptoms were found in cycles 
with higher concentrations of both estradiol and progesterone [39]. It appears that 
women with PMDs are more sensitive to developing negative mood and physical 
symptoms with the exposure to normal concentrations of ovarian sex steroids. 
Women with PMS, but not asymptomatic women, had a negative affective 
response to the administration of physiological doses of exogenous estradiol or 
progesterone after having achieved a ‘chemical menopause’ by receiving a 
gonadotrophin-releasing hormone (GnRH) agonist [40]. The metabolites of 
progesterone (and corticosterone) have psychoactive properties and have been 
known for almost a century to produce sedation in animals. These effects are not 
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mediated through the classical progesterone receptor. Given this evidence, 
researchers have postulated that a metabolite of progesterone may contribute to 
the generation of the affective and physical symptoms of PMDs through the 
modulation of a different receptor mechanism. 
1.4.2 Gamma Amino Butyric Acid: 
Temporal onset of PMS begins with ovulation and is likely related to 
progesterone production. The rising concentration of estradiol in the late 
follicular phase or a hormonal milieu consisting of estrogen alone fails to 
produce PMS symptoms. However, progesterone itself did not seem to be 
speciﬁcally the key, leading researchers to investigate the role of the neuroactive 
metabolites of progesterone that were known to affect mood and behaviour. In 
the ovary and the brain, progesterone is metabolized to form the potent 
neuroactive steroids, 3-alpha-hydroxy-5-alpha-pregnane-20-one 
(allopregnanolone or ALLO) and 3-alpha-hydroxy-5beta-pregnane20-one 
(pregnanolone). These metabolites act as positive allosteric modulators of the 
GABA neurotransmitter system in the brain. The main inhibitory 
neurotransmitter in the brain, GABA, is a widely distributed neurotransmitter in 
the central nervous system (CNS) and evidently is an important regulator of 
stress, anxiety, vigilance, alertness and seizures [41] GABA is derived from 
glutamate, which is synthesized in series of steps by the Krebs cycle, and is then 
decarboxylated to GABA by the rate-limiting enzyme, glutamic acid 
decarboxylase, exclusively found in GABAergic neurons. GABA is then stored 
in vesicles found in the presynpatic terminal of GABAergic neurons. Three 
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subtypes of GABA postsynaptic receptors have been identiﬁed: GABAA, 
GABAB and GABAC receptors. However, it is the GABAA receptor that is the 
site of action of endogenous agents such as neuroactive steroids derived from 
progesterone or synthesized de novo in the CNS, as well as exogenous agents 
such as progestogens (after metabolism to reduced steroids), benzodiazepines, 
barbiturates, alcohol and anticonvulsants [41]. GABAA receptors are 
transmembrane protein complexes composed of alpha, beta, delta and gamma 
subunits that function as ion channels. For example, when GABA binds to the 
GABAA receptor it causes a conformational change in the protein complex that 
results in rapid and transient opening of chloride ion channels. Chloride inﬂux 
results in hyperpolarization of the membrane and decreases the likelihood of 
depolarization by excitatory neurotransmitters. This is in contrast to the slow 
classical genomic effect of cystosolic activation of steroid hormone receptors. 
Binding of alpha reduced progesterone, corticosterone and testosterone 
metabolites, barbiturates, benzodiazepines at an allosteric site on the GABAA 
receptor results in activation of receptor and increases neuronal inhibition via a 
direct and rapid mechanism as described above [41]. Research has shown that 
ALLO, by binding GABAA receptors, plays an important physiological 
modulatory role in changing the sensitivity of GABAA receptors for GABA. [41] 
This modulatory effect is accomplished by altering the subunit composition of 
the receptor, rending the receptor temporarily insensitive to modulation by 
neurosteroids. These compositional alterations of the GABAA receptor isoforms 
are postulated to be important in the aetiology of PMDs. Initially a deﬁciency of 
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these neuroactive steroids was postulated. For example, acute treatment with 
ALLO has been shown to have anxiolytic, antidepressive and anticonvulsant 
effects. Similarly, decreased neuroactive steroids have been associated with 
anxious and depressive behavior [42]. Reduced progesterone metabolites such as 
ALLO have been measured in PMS and asymptomatic women in the luteal phase 
and some but not all studies have shown a deﬁciency or an association with mood 
in women with PMS.[43,44] In addition to the importance of concentration of 
these neuroactive metabolites in determining agonistic effect on GABAA 
receptor, the duration of exposure also plays a critical role. For example, whereas 
acute, very short-term ALLO exposure decreases stress and anxiety, chronic 
exposure has been shown to produce an anxiety-like reaction [45]. Decreased 
expression and binding to the GABAA receptor as well as uncoupling of the 
receptor from anxiolytic modulators can result in increased anxiety. GABAA 
receptor conﬁguration changes after exposure to ALLO in the luteal phase such 
that GABAA receptor function and modulation vary throughout the menstrual 
cycle. Studies completed in rodents have shown that acute and prolonged 
exposure as well as withdrawal from ALLO attribute to an increased in alpha-
4,17 gamma-2 [46] and delta [47] subunit of GABAA receptors. This GABAA 
plasticity subsequently results in temporarily decreased sensitivity to GABA and 
GABA agonists and enhances anxiety-like behavioural changes. Although the 
GABA subunit studies were performed in rats, human studies using saccadic eye 
velocity as a proxy for GABAergic activity support the postulate that these 
alterations in GABAA subunit conﬁguration and GABAergic activity likely 
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contribute to the negative mood symptoms associated with PMS [48]. Sundstro 
¨m and Ba ¨ckstro ¨m (1998) [49] demonstrated that administration of a selective 
serotonin reuptake inhibitor (SSRI) in the luteal phase to women with PMS 
increased the saccadic eye velocity to that of control women, suggesting a re-
instatement of GABAergic sensitivity by augmenting serotonin. 
1.4.3 Serotonin: 
Serotonin (5-HT, 5-hydroxytryptamine) has been implicated in the 
modulation of mood, eating, arousal and circadian rhythms. Serotonin depletion 
through dietary or pharmacological means leads to anxiety and depressive like 
symptoms. The role of serotonin in PMS has been supported by various lines of 
evidence. PMS symptoms overlap symptoms associated with reduction in 
serotonin transmission [50] These symptoms include depression, mood swings, 
irritability, self-deprecation, poor impulse control, sleep disturbance, anxiety, 
aggression, decreased pain threshold, carbohydrate cravings and difﬁculty in 
concentrating. In addition, serotonergic function has been shown to be altered 
during the luteal phase of the menstrual cycle in women with PMS. For example, 
decreased platelet uptake of serotonin [51], decreased baseline whole blood 
serotonin [52] and decreased platelet monoamine oxidase (MAO) activity [53] 
have all been shown to occur during the luteal phase of the menstrual cycle. 
Tryptophan loading tests in women with PMS are abnormal compared with the 
results for asymptomatic women. Serotonin metabolism is also modulated in part 
by ovarian sex steroids. Ovarian sex steroids have also been implicated in 
serotonin uptake, turnover, binding and transport. Finally, administration of 
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drugs augmenting serotonergic neurotransmission is effective for treatment of 
PMDs. The role of serotonin is further supported by lack of signiﬁcant 
improvement of PMS symptoms with antidepressants that only augment 
norepinephrine and not serotonin. Taken together, the evidence suggests that 
serotonergic dysregulation may play an important role in symptomatology of 
PMS and that serotonin in concert with other neurotransmitters such as GABA 
are important in the pathophysiology underlying the disorder. 5-HT is 
synthesized in serotonergic neurons. Speciﬁcally, the amino acid, tryptophan, is 
sequentially altered by two enzymes in the CNS. First, tryptophan hydroxylase, 
the rate-limiting enzyme, produces 5hydroxytryptophan, then L-aromatic amino 
acid decarboxylase decarboxylates 5-hydroxytryptophan to 5-HT. 5-HT is then 
stored in vesicles in the presynaptic terminal, ready to be released upon arrival of 
nerve impulses. Once 5-HT is released into the synaptic cleft, it is subsequently 
inactivated primarily by reuptake through the high afﬁnity pre-synaptic 
membrane serotonin transporter (SERT). An important clinical target for 
therapeutic drugs, SERT, is the site of action of the SSRIs. Serotonergic activity 
in the brain is affected by estrogen and progesterone; speciﬁcally sex steroids can 
modify serotonin availability at the neuronal synapses. For example, estrogen has 
been shown to increase degradation of MAO, enzyme responsible for oxidation 
of monoamines, and catechol-o-methyl-transferase (COMT), enzyme responsible 
for degradation of catecolamines. Estrogen’s role in increasing degradation of 
MAO and COMT results in augmenting action of serotonin in regulating the 
availability of free tryptophan in the CNS and improving clinical effect of SSRIs. 
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In contrast, progesterone increases MAO activity, therefore decreases 5-HT 
availability, which may result in depressed mood [53]. 
1.4.4 Brain Neurocircuitry: 
Neuroimaging studies focusing on hormonally mediated changes across the 
menstrual cycle and in women with PMDs compared with asymptomatic controls 
can provide valuable information regarding the underlying neurophysiological 
abnormalities in PMS and PMDD. For example, an early positron emission 
tomography (PET) study showed that regional cerebral blood ﬂow in the 
prefrontal cortex was attenuated by pharmacological ovarian suppression, and 
this was subsequently normalized with estrogen or progesterone replacement 
[54]. A study employing protein magnetic resonance spectroscopy showed 
increased cortical GABA concentrations in the luteal phase of women with 
PMDD when compared with follicular phase; however, healthy subjects showed 
decreased cortical GABA [55]. The authors concluded that abnormal GABAA 
receptor functioning could reduce sensitivity to GABA agonists, including 
neuroactive steroids such as the pregnone metabolites [55]. A PET study looking 
at serotonin-1A receptors showed signiﬁcantly smaller increment in receptor 
binding between the follicular and the luteal phase scans in women with PMDD 
compared with controls [56]. In one study using functional magnetic resonance 
imaging, neural response was evaluated to an emotional Go/No-Go task designed 
to provoke negative emotion [57]. Researchers found that women with PMDD 
were less able than controls to inhibit incorrect responses to affectively negative 
words. Control subjects showed more activity during the late luteal phase 
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compared with the follicular phase within the anterior-medial orbitofrontal cortex 
(OFC) and less activity in the lateral OFC, insula and posterior cingulate cortex. 
However, PMDD subject showed more activity in the amygdale during the late 
luteal compared with the follicular phase and less activity in the OFC [57]. This 
was interpreted as diminished impulse control via prefrontal ‘top-down’ 
modulation of the limbic system. In a more recent study, investigators desired to 
map functional brain abnormalities associated with negative mood states in 
PMDD. PET with [18F] ﬂuorodeoxyglucose was used to assess regional cerebral 
metabolism across the menstrual cycle in women with PMDD and asymptomatic 
participants. Women with PMDD showed an increase in cerebellar activity from 
the follicular phase to the late luteal phase and this was correlated with 
worsening of mood. The increased activity was localized primarily to cerebellar 
regions that have been previously described as the ‘limbic’ cerebellum. The 
cerebellum is rich in GABA receptors containing the delta and alpha subunits and 
as noted above, animal models suggest women with PMDs may have deﬁciencies 
in mechanisms regulating GABA subunits. The increased cerebellar activity 
could reﬂect decreased GABA-mediated inhibition during the symptomatic luteal 
phase [58]. 
 1.5 Impact of PMS: 
Impact of PMS on various areas of life and health includes such as: 
✓ These symptoms can vary between individuals and have the potential to affect 
work, personal life, and place additional stress on a relationship [59, 60]. 
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✓ Significant correlations were found between the mean premenstrual severity and 
functional impairment. The severity of premenstrual affective symptoms was 
related to social impairment. The severity of psychological symptoms was 
correlated with occupational impairment. These findings confirm the prominent 
role of premenstrual affective symptoms and support classification guidelines 
focusing on both affective and physical changes [61]. 
✓ The marital relationship of PMS couples deteriorated in the luteal cycle phase 
[62]. 
✓ Moderate-to-severe PMS/PMDD seems to be associated with work productivity 
impairment and increased absenteeism, and thus poses a potential economic 
burden [63]. 
✓ Premenstrual period is a risk period for associated psychiatric disorders 
exacerbations, as the obsessive-compulsive disorder, more severe alcohol intakes 
in case of alcoholism, symptoms increase in schizophrenics, or higher rates of 
suicide attempts [64]. 
✓ Women with PMS are likely to have sexual difficulties and a higher level of 
sexual distress, emphasizing the importance of the sexual aspects of PMS in 
clinical practice [65]. 
✓ The presence of PMS is a risk factor for sexual dissatisfaction in women of 
reproductive age [66]. 
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✓ Women with PMS and PMDD have a higher odds of BN, independent of co-
morbid mental health conditions. PMS and PMDD may be important co-
morbidities to BN to consider in clinical settings, and future research should 
investigate whether PMS and PMDD affect the onset and duration of bulimic 
symptoms as well as the potential for shared risk factors across disorders [67]. 
✓ This study demonstrates a strong, independent association between PMS/PMDD 
and trait anger among a representative sample of female suicide attempters. It is of 
major interest for clinicians in view of addressing a substantial public health 
problem among women of reproductive age [68]. 
✓ Serum levels of inflammatory markers, including interleukin (IL)-2, IL-4, IL-10, 
IL-12 and interferon (IFN)-γ were positively associated with menstrual symptom 
severity and/or PMS in young women [69]. 
✓ PMS/PMDD is an important risk factor for PPD. Women endorsing a history of 
PMS/PMDD should be monitored during the perinatal period [70]. 
✓ The diastolic blood pressure is elevated in young adult women experiencing PMS 
[71].  
✓  PMS had an elevated frequency in medical students. In students with PMS, rate of 
depression was higher than students without PMS [72]. 
1.6 Diagnosis: 
There are no specific physical findings or laboratory tests that can be utilized to 
make the diagnosis of PMS. In a Practice Bulletin published in the year 2000, The 
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American college of obstetricians and gynecologists (ACOG) defined diagnostic 
criteria for PMS based on the work of Mortola (1990) describes that PMS can be 
diagnosed if at least one of the affective and one of the somatic symptoms are 
reported five days prior to the onset of menses in the three prior menstrual cycles. 
The symptoms must be prospectively recorded in at least two cycles and must 
cease within 4 days of onset of menses and not recur until after day 12 of the 
cycle. These symptoms must be recorded in the absence of pharmacologic therapy, 
or use of hormones, drugs, or alcohol, and cause identified dysfunction in social or 
work-related activities [73]. Premenstrual symptoms may cause several difficulties 
for women including impairment in physical functioning, psychological health and 
severe dysfunction in social or occupational realms [74]. In young adolescents, 
symptoms might particularly affect school functions, and social interactions in a 
negative way [75]. Previous studies have also shown that women with 
premenstrual disorders have a poor health-related quality of life [76, 77].  
1.7 Conventional therapies: 
1.7.1 General Principles of Treatment: 
When managing women with PMS, there are certain principles that should be 
adhered to. Even though not evidence-based, there is little doubt that reduction of 
stress for instance is a great help in ameliorating the symptoms. Also, dietary 
measures such as avoidance of carbohydrate binges and limitation of alcohol and 
caffeine intake are often of benefit. There are data from non-randomised trials 
suggesting that exercise improves PMS symptoms.However, in cases of moderate 
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to severe PMS, it is important that medical therapy is instituted sooner rather than 
later to avoid unnecessary suffering. Women with marked underlying 
psychopathology as well as PMS should be referred to a psychiatrist. Symptom 
diaries (e.g. the DRSP) should be used to assess the effect of treatment [78]. 
1.7.2 Service Delivery:  
Primary care should deal with most cases of PMS. Awareness of the condition 
and training in its management is essential. Ideally, women with severe PMS 
should be managed by a multidisciplinary team, which might comprise a hospital 
or community gynaecologist, psychiatrist or psychologist, dietician and 
counsellor. While such services are rarely provided in any National Health 
Service (NHS) setting, referral to gynaecologists should be reserved for women 
who have been fully evaluated as having severe PMS and when simpler forms of 
therapy have been explored. Where there is multidisciplinary provision of care, 
this is of benefit both from the diagnostic and therapeutic point of view, giving 
the ability to offer a broad range of interventions from lifestyle interventions and 
cognitive behavioural therapy (CBT) to gynaecological interventions [79]. 
1.7.3 Complementary Therapies (CAMs): 
When treating women with PMS, complementary medicines may be of benefit, 
but clinicians need to consider that data from clinical studies are limited and 
underpowered. Interactions with conventional medicines should also be 
considered. The referring clinician retains legal responsibility for the patient’s 
well being when they refer patients to complementary therapists. It is difficult to 
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assess the true value of most of these therapeutic interventions because they are 
freely available without prescription or physician recommendation, with little 
regulation of efficacy or safety. Most are not licensed or registered for treatment 
of PMS. The Medicines and Healthcare products Regulatory Agency (MHRA) 
and European regulatory authorities are aiming to rectify the situation by 
insisting that all complementary therapies are registered by 2011 or withdrawn 
from sale. This section reviews the recent evidence for some of the evidence-
based ‘alternative’ interventions that have been used to treat PMS. Treatments 
have been selected where reasonable efficacy data exist [randomised controlled 
trial (RCT) data if possible [79].  
1.7.4 Vitamin B6 OTC:  
Vitamin B6 is often used to treat PMS without clear evidence of its efficacy [80]. 
The recommended dietary allowance for vitamin B6 is around 2.0 mg/day and 
deficiency of vitamin B6 is rare. Due to unproven efficacy of vitamin B6 in 
treating PMS, a systematic review of published and unpublished randomised 
placebo-controlled trials of effectiveness of vitamin B6 in the management of 
PMS was undertaken. Nine published trials representing 940 patients were 
reviewed. The main outcome measure was an improvement in overall 
premenstrual symptoms. The overall methodology of the trials identified was of 
poor quality, with none of the trials justifying patient numbers with a power 
calculation. The odds ratio (OR) in favour of vitamin B6 relative to placebo for 
an improvement in overall PMS was 2.32 (95% CI 1.95–2.54). No conclusive 
evidence of vitamin B6 toxicity was reported and there was no dose-related 
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response to treatment. There is no rationale for giving daily doses of vitamin B6 
in excess of 100 mg, especially following the recommendation from the 
Department of Health and the Medicine Control Agency in 1999 to restrict the 
dose of vitamin B6 available generally to 10 mg and to limit the dose sold by a 
pharmacist to less than 50 mg[81]. 
1.7.5 Magnesium OTC:  
Preliminary studies suggest that magnesium may also be helpful in PMS. A 
double-blind, placebo-controlled study of 32 women found that magnesium taken 
from Day 15 of the menstrual cycle to the onset of menstrual flow could 
significantly improve premenstrual mood changes [82]. Another small, double-
blind, preliminary study found that regular use of magnesium could reduce 
symptoms of PMS related fluid retention [83].In this study, 38 women were 
given magnesium or placebo for 2 months. One small, double-blind study (20 
participants) found that magnesium supplementation with vitamin B6 might help 
prevent menstrual migraine [84]. 
1.7.6 Calcium/Vitamin D OTC:  
Studies suggest that blood calcium and vitamin D levels are lower in women with 
PMS and that calcium supplementation may reduce symptom severity, but it is 
unknown whether this may prevent the initial development of PMS. In a recent 
case control study, after adjustment for risk factors, women in the highest quintile 
of total vitamin D intake (median, 706 IU/day) had a relative risk of 0.59 (95% 
CI 0.40–0.86) compared with those in the lowest quintile (median, 112 IU/day) 
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(p = 0.01 for trend) [85]. The intake of calcium from food sources was also 
inversely related to PMS; compared with women with a low intake (median, 529 
mg/day), participants with the highest intake (median, 1283 mg/day) had a 
relative risk of 0.70 (95% CI 0.50–0.97) (p = 0.02 for trend). The intake of 
skimmed or low-fat milk was also associated with a lower risk (p<0.001). A high 
intake of calcium and vitamin D may therefore reduce the risk of PMS but large-
scale clinical trials addressing this issue are required. At present, the only 
interventional data are from small trials. More data are required to determine 
efficacy and to optimise regimens[86-88].  
1.7.7 Isoflavones (e.g. soy/red clover) OTC:  
In a 24-week, double-blind study, 49 women with menstrual migraines received 
either placebo or a combination supplement containing soy isoflavones, dong 
quai and black cohosh extracts. The treatment group showed a significantly 
greater improvement than the placebo group [89]. Recent data from the author’s 
unit demonstrate a benefit with red clover isoflavones but this is not statistically 
significantly different to placebo [90].  
1.7.8 Agnus castus OTC:  
Agnus castus is the best researched CAM for PMS but a lack of standardised 
quality controlled preparations is a problem. The fruits of Vitex agnus castus (the 
chaste tree) contain a mixture of iridoids and flavonoids. The mechanism of 
action may be related to modulation of stress-induced prolactin secretion via 
dopamine, without directly affecting luteinising or follicle-stimulating hormones. 
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A study was undertaken to compare the efficacy and tolerability of agnus castus 
with placebo in 170 women with PMS. Results showed improvement in the main 
variable was greater in the active group compared with placebo group [91]. 
Patient acceptance was high and side effects were few and mild. A previous 
double-blind trial compared agnus castus to vitamin B6 (pyridoxine) instead of 
placebo [92]. The two treatments proved equally effective. In a recently 
published study, 217 women were randomised. Efficacy was assessed using the 
Chinese version of the PMS diary (PMSD). The total PMSD score in the third 
cycle was highly significantly lower than the baseline in both groups (p<0.0001). 
The difference in the mean scores from the baseline to the third cycle in the 
treatment group (22.71 ± 10.33) was significantly lower than the difference in the 
placebo group (15.50 ± 12.94, p<0.0001) [93]. 
1.7.9 St John’s Wort OTC (Hypericum perforatum):  
(St John’s Wort) is a herbal remedy shown to alleviate mild to moderate 
depression. However, there has been no clinical investigation on its effectiveness 
in treating PMS apart from one case report and a small, prospective, open, 
uncontrolled, observational pilot study [94, 95] The study investigated whether 
Hypericum could relieve PMS in a small group of women and tested the methods 
for conducting future RCTs with this preparation. Nineteen women with PMS 
used  Hypericum tablets for two complete menstrual cycles. There were 
significant reductions in all outcome measures. The improvement was 51% when 
the PMS scores were measured between the baseline and the end of the trial, with 
over two-thirds of women demonstrating at least a 50% decrease in symptom 
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severity. Symptoms which improved the most were emotional and cognitive, 
which correlates with evidence showing that Hypericum has positive effects on 
mood and that it may moderate brain neurotransmitters.  
1.7.10 Evening primrose oil OTC IE: 
 Evening primrose oil, a rich source of gamma linoleic acid, is often used as a 
treatment for severe PMS. However, the evidence for efficacy in this condition is 
poor. A prospective, randomised, double-blind and placebo-controlled trial 
showed that there was no significant difference in the scoring between the active 
and placebo groups over six cycles. These findings indicate that the improvement 
experienced by these women with moderate PMS was solely a placebo effect 
[96]. A metaanalysis of the data has also concluded that evening primrose oil is 
ineffective in the treatment of severe PMS [97]. Only cyclical mastalgia has been 
shown to respond to this treatment [98]. 
1.7.11 Exercise and Yoga: 
 A primary example of a nonpharmacologic therapy with is exercise. Most of the 
published studies on exercise and PMS have shown a benefit. These studies are 
hampered by small study size and the inability to double blind. Exercise seems to 
reduce mood symptoms and physical symptoms of breast tenderness and 
bloating. One pro- posed underlying pathophysiology is the enhancement of 
central opiate activity associated with exercise. Because of other significant 
health benefits of regular exercise and data suggesting the relief of PMS 
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symptoms, exercise can be considered a first-line therapy among the 
nonpharmacologic interventions [99].  
1.8 Aromatherapy 
Aromatherapy, also referred to as Essential Oil therapy, can be defined as the art 
and science of utilizing naturally extracted aromatic essences from plants to 
balance, harmonize and promote the health of body, mind and spirit. 
Aromatherapy is the practice of therapeutic use of essential plant-based oils. 
Essential oils and aromatherapy have been used in the care of women for 
centuries [100]. 
Aromatherapy can be defined as a controlled use of aromatic plant oils for 
therapeutic or preventive purposes. It can be applied through aerial diffusion, 
direct inhalation, and topical applications. The use of essential oils for 
therapeutic and spiritual purposes can be dated back to ancient civilizations, 
including the Chinese, Indians, Egyptians, Greeks, and Romans. However, the 
beginning of contemporary aromatherapy is often attributed to the pioneer work 
of the chemist René-Maurice Gattefossé and Doctor Jean Valnet from the early 
twentieth century in France. It was not until the 1980s that aromatherapy became 
popular in the United States and began to gain attention for its potential clinical 
applications. Nevertheless, despite its popular use in both the community and 
health care settings today [101, 102], there is still a paucity of empirical evidence 
supporting the efficacy of aromatherapy in many therapeutic claims [103]. 
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1.8.1 Mechanism of aromatherapy:  
Essential oils are absorbed into the body in many different ways.  Once inside the 
body, essential oils have the ability to enter the bloodstream and therapeutic 
benefits can be achieved.  They can enter the body through inhalation, ingestion, 
or absorption through the mucous membranes and skin. Essential oils can enter 
the bloodstream by being inhaled through the nose, which is the fastest direct 
route into the body.  Researchers Gatti and Cajola noted that odors produced an 
immediate effect on respiration, pulse, and blood pressure, and concluded that 
odors had produced by reflex action a dramatic effect on the functioning of the 
nervous system [104].  
The olfactory system allows the sense of smell. The nose is the first part of the 
olfactory system. Smell is a chemical reaction – receptors in the brain respond to 
chemicals in the essential oil [105]. The process of olfaction consists of five 
stages – detection, transmission, perception, analysis, and storage.  An aroma 
must pass through all five stages in order to be stored in the brain for future 
recall.  
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The Olfactory and Limbic Systems   
 
Figure 1: (From Battaglia S. 1995.  A schematic of the olfactory system with its 
primary and secondary paths to other regions in the brain.  In Battaglia, S (ed.), 
The Complete Guide to Aromatherapy, Australia:  The Perfect Potion, p. 101)  
During detection, a scent is carried into the nostril and the molecules move up the 
nose to the olfactory epithelium. Here the molecules attach to millions of hair 
like receptors that are connected to the olfactory bulb.  Different scents bind to 
different receptors. Once the scent binds to a receptor, it is transmitted into an 
electromagnetic impulse and travels to the two olfactory bulbs.  These bulbs 
connect directly to the limbic system of the brain where the scent is perceived.  
The limbic system is comprised of the amygdala, septum, hippocampus, anterior 
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thalamus, and hypothalamus. The limbic system influences emotions, motivation, 
instinctive behaviors, learning, and memory [106]. 
 It can activate emotional reactions from aromas, and send these coded aroma 
messages to other parts of the brain. Once the aroma is perceived, the mind and 
body analyze the scent.  This is accomplished by the reticular system of the brain, 
which integrates emotions with memories.  The hypothalamus, the brain’s basic 
center for drives and emotions may be activated, which stimulates the pituitary 
gland.  The pituitary gland produces hormones that affect the body's other glands.  
These hormones trigger physiological, psychological, and emotional reactions 
that influence feelings and behavior.  The brain will then store the aroma.  It may 
compare input about the aroma with other senses in the body.  The brain will 
form a conclusion as to what the aroma is, and store the information for future 
recall. In this manner, certain aromas or scents will trigger particular emotional 
reactions.  Once an aroma is stored in the brain, each subsequent time it is 
inhaled the brain and the body will evoke the same response.  By directly 
inhaling an essential oil, the brain is able to analyze and store the scent, as well as 
the responses in the body the scent invokes.  In this way, essential oils are 
therapeutic by inhalation. Essential oils are also effective through inhalation if 
the desired therapeutic effect concerns the respiratory system, as the oils will 
travel down the trachea and into the lungs when inhaled.  Once in the respiratory 
system, the oils can have dramatic effects on respiratory disorders as they come 
in contact with the mucous membranes in the nose, as well as the tissue of the 
lungs and bronchi.  Essential oils can be inhaled using an atomizer, diffuser, 
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vaporizer, through steam vapor, or directly from the bottle. Essential oils are lipid 
soluble and can be absorbed directly into the bloodstream through the skin. The 
study of where essential oils go when they are absorbed into the body and how 
they are absorbed and eliminated is called pharmacokinetics.  Straehli, who 
researched pharmacokinetics in 1940, found that all the essential oils appear in 
the breath following absorption through the skin, although the time interval 
differs with each essential oil [107].  
The lipophilic nature of essential oils means they can pass the blood brain barrier.  
Their affinity for lipid rich tissues like those of the central nervous system 
facilitates an exchange of essential oil constituents from the blood into the 
nervous system. Once the oils have reached the central nervous system, their 
effects can travel through the body very quickly. When essential oils are applied 
to the skin surface, they are absorbed into the epidermis, the stratum corneum, 
and to the lower layers of the dermis.  The oils can travel down into the dermis 
via the sweat glands or the hair follicles.  Once in the dermis, the oils move into 
the capillaries located here and travel into the bloodstream.  Once in the blood 
stream, they are able to quickly travel through the body [108].  
1.8.2 Physiological effects of aromatherapy: 
Physiological effects of aromas can be divided into two types: those which act 
via the stimulation of the nervous system and those which act directly on an 
organ or tissue via an effector receptor-mechanism [109]. The physiological 
measures are all under the control of the nervous system. In general, the nervous 
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system of higher organisms can be classified into two major sections, the central 
nervous system (CNS) and the peripheral nervous system.  The CNS includes the 
brain and spinal cord. Two important functions of the CNS are to receive and 
process sensory information and to regulate bodily movements. The peripheral 
nervous system refers to the nervous tissues outside the brain and spinal cord, 
including the cranial and spinal nerves. The peripheral nervous system is further 
divided into the somatic nervous system, concerned with muscular activities, and 
the autonomic nervous system (ANS) which controls visceral structures (glands 
and organs of body). In addition, the function of the ANS is to regulate the 
internal and relatively involuntary responses that are associated with emotions. 
Finally, the ANS is subdivided into the sympathetic nervous system (SNS) and 
the parasympathetic nervous system (PNS). These two branches differ in 
functions. The SNS is dominant in situations requiring mobilization of energy 
whereas the PNS is dominant in a rest situation. Some organs are innervated by 
only one division of the ANS (e.g., the sweat glands, peripheral blood vessels, 
and adrenal glands are innervated solely by the SNS). Most organs are innervated 
by both the SNS and the PNS. In those cases, the SNS and the PNS branches 
usually produce opposite reactions. Among the most significant of the bodily 
reactions produced by the SNS are pupil dilation, inhibition of salivation (causing 
a dry mouth), secretion of sweat (causing clammy hands), constriction of blood 
vessels in the periphery of the body (causing cold hands and feet), dilation of 
blood vessels in the muscles and brain, increase of heart rate, increase of blood 
pressure, speeding of breathing rate, and inhibition of digestive processes. 
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Among the bodily reactions produced by the PNS are pupil constriction, increase 
of salivation, decrease of heart rate, decrease of blood pressure, decrease of 
breathing rate and increase of digestion and peristaltic processes [110]. 
Evaluation of the effects of aromas on the nervous system may be divided into 
two different forms of arousal, the cortical arousal such as brain wave activity 
and the autonomic arousal such as heart rate, skin conductance. Decreases of the 
cortical arousal and/or the autonomic arousal are interpreted in terms of a 
sedative/relaxing effect of aromas. In contrast, increases of the cortical arousal 
and/or the autonomic arousal are interpreted in terms of a stimulating effect of 
aromas. The changes of physiological parameters in response to aromas are 
reviewed throughout this paper. They are heart rate, blood pressure, 
electrodermal activity, electroencephalogram (EEG), contingent negative 
variation (CNV), and eye blink rate or pupil functions [111]. 
1.8.3 Clary sage and Aromatherapy: 
Clary sage is a gift to the female and has a rejuvenating effect on the endocrine 
system and balances the pituitary and is specifically indicated in treating PMS 
[100]. The composition of the essential oils obtained from different parts of both 
wild and cultivated forms of Salvia sclarea L. were investigated by both GC and 
GC/MS. The principal components of the oils were linalool (22–32%) and linalyl 
acetate (25–51%). It was found that the oil composition was not influenced by 
the part of the plant from which oil was obtained, except for the leaves [112]. 
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Figure 2: Clary Sage 
Tisserand [113] suggested that clary sage has functions similar to estrogen, such 
as normalizing the menstrual cycle, promoting menstruation, and strengthening 
the uterus [114]. Aromatherapy is perceived to be a safe therapy [115]. Essential 
oils have been used for several hundred years and are used regularly today by the 
public for stress-management and for minor ailments [116]. However, the 
therapeutic effects of aromatherapy are not well supported by clinical studies.  
Clary sage oils contain linalyl acetate. Linalyl acetate has been shown to decrease 
blood pressure, heart rate and respiratory rate, and decrease salivary cortisol and 
CgA concentrations [117, 118]. Research has also revealed that clary sage oils 
act on neurotransmitters in the brain.  
Salvia sclarea L. (Lamiaceae) essential oil was tested in a pilot trial for 
modulation of depression signs in 22 women [119]. Normal and depressive 
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tendencies and serum parameters in menopausal women acutely inhaling clary 
sage oil were assessed before and after exposition. Given the comparison 
between pre-inhalation and post-inhalation of clary sage oil, 5-HT plasma 
concentrations increased signiﬁcantly, and plasma cortisol levels decreased 
signiﬁcantly for both normal and depressive menopausal women [119]. It should 
be mentioned that this pioneering clinical trial contributed by measuring 
physiological changes alongside of behavioral alterations in women with 
depressive symptoms after acute clary sage oil inhalation. The antidepressant 
effects of essential oil of Salvia sclarea L. were assessed in the FST in rats. The 
acute exposition to this oil, via intraperitoneal and inhalation, reduced immobility 
time similar to conventional antidepressant drugs [120]. The antidepressant 
effects of this essential oil seem to be mainly mediated by the activation of 
dopamine and 5-HT neurotransmission [120]. In fact, the pretreatment with 
haloperidol (Dopamine receptor antagonist), SCH-23390 (D1 receptor 
antagonist), but also buspirone (5-HT1A partial agonist) blocked the 
antidepressant effect of this essential oil [120]. The principal constituents of 
Salvia sclarea L. oil include linalyl acetate (64%), linalool (21%), and geraniol 
(2.6%) [121]. Linalool and geraniol have showed consistent antidepressant 
actions inrodents after acute administrations [122, 123–125. This effect of 
linaloolin rodents were prevented with WAY100,635 (5-HT1A receptor 
antagonist) and yohimbine (α2-receptor antagonist), thus reinforcing the role 
mediated by monoaminergic neurotransmission in the antidepressant effects of 
linalool [123]. Ultimately, the antidepressant of the Salvia sclarea L. essential oil 
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seems to be due to the synergic effects of bioactive isolated compounds. The 
most studied isolated compounds are eugenol [126,127] and linalool 
[122,123,124]. Studies suggest robust antidepressant-like actions as demonstrated 
in distinct behavioral tests (FST and TST) performed in different labs around the 
world. The main target of the antidepressant action of eugenol is the MAO 
enzyme [127]. This compound preferentially inhibits the MAOA activity, and 
after chronic administrations increases the neurotrophic factor, BDNF, a 
mechanism of action shared with conventional antidepressants. Concerning 
linalool, main constituent of the extracted lavender and clary sage oil [119,128], 
acute studies suggestive of antidepressant actions support the activation of 
monoamine 5-HT1A and α2-receptors [123]. 
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2. AIMS AND OBJECTIVES 
 
AIM: 
To evaluate the effects of clary sage oil in relieving the symptoms of  
Premenstrual syndrome. 
 
OBJECTIVES: 
To assess the effects of clary sage oil on physiological, psychological and 
behavioural symptoms of Premenstrual syndrome. 
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3. REVIEW OF LITERATURE 
According to a study conducted in May 2013, it indicates that lavender 
aromatherapy has a potential therapeutic modality could alleviate premenstrual 
emotional symptoms, which, at least in part, is attributable to the improvement of 
parasympathetic nervous system activity. This study further implies that HRV 
could evaluate the efficacy of aromatherapy using various fragrances to relieve 
premenstrual symptoms, and ultimately, support the mind and body health of 
women [129]. 
Premenstrual Syndrome is a psycho-neuroendocrine stress related disorder 
and more than 300 treatment modalities for PMS show that the existing remedies 
have not provided satisfactory help to relieve PMS. 61points relaxation exercise 
(61-PR), a relatively less known hatha yoga technique, is a successful means of 
stress relaxation and is expected to relieve PMS as well. Therefore, Dvivedi et al., 
(2008) conducted a study on 50  clinically healthy women volunteers who were 
in their reproductive age group and in their premenstrual period, from which a 
control group (n = 20) and a PMS group (n = 30) based on the symptoms were 
identified. In both groups basal heart rate (HR/min), systolic (SBP; mmHg) and 
diastolic blood pressure (DBP; mmHg), electromyogram (EMG; mV), 
electrodermal galvanic activity (EDG; microv), respiratory rate (RR/min) and 
peripheral temperature (T; degrees F) were recorded and the subjects were taken 
through a guided 61PR. The results suggested a reduction in sympathetic activity 
by 61-PR, also the high basal sympathetic tone present in subjects of PMS group 
due to stress is considerably reduced by relaxation. 61-PR is effective in providing 
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relief from PMS and may be a useful adjuvant to medical therapy of PMS and 
other stress disorders [130]. 
Pullon, Reinken and Sparrow (1989) conducted a survey among 1826 
females in Wellington in order to collect data about their gynecological health and 
general health along with detailed history of last menstrual period. Majority of 
females had had their menstrual cycle within last one month. Out these females, 
85% had suffered from premenstrual symptoms of some or the other kind and 
were asked whether they followed any advice, treatment, medical help or self-help 
for PMS. Self-help was tried by 990 women and 416 went for medical help. 
Exercise, vitamin B6 supplement, and rest were the most common self-help 
practices tried by half of the females surveyed. Rest, exercise and keeping a record 
of PMS were helpful in 80% of females. There was a marked placebo effect. 
Treatments offered by doctors included mefenamic acid, vitamin B6, oral 
contraceptives and diuretics, but it was difficult to further evaluate the effect of 
these treatment options. The four PMS syndromes which were suggested are PMS-
various, PMS-irritable and intolerant, PMS-bloat, and PMS-breast [131].    
Han et al., (2006) conducted a research in order to find out the effect of 
aroma therapy on symptoms of dysmenorrheal and menstrual cramps. 67 female 
students were selected who had complaints related to menstrual cycle. The 
inclusion criteria were rating of menstrual cramps should be more than 6 on a 
visual analogue scale, no reproductive or systemic diseases, and no use of 
contraceptive drugs. Three groups were formed i.e. experimental, control and 
placebo group. Topical application of aroma oil was done in the females of 
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experimental group. This aroma oil was prepared using 1 drop rose (Rosa 
centifolia), a drop of clary sage (Salvia sclarea), and 2 drops lavender (Lavandula 
officinalis) in almond oil (5 cc). However, the placebo group received treatment 
with almond oil only whereas control group was not given any treatment. Visual 
analogue scale was used to assess the severity of menstrual cramps and 
multidimensional verbal scoring system was used to measure dysmenorrhea 
severity. It was revealed that experimental group suffered from significantly lesser 
menstrual cramps as compared to two other groups. It was concluded that 
menstrual cramps can be reduced by topical application of aroma oils consisting of 
rose, clary sage, and lavender. Therefore, aromatherapy can be a good alternative 
option for females who suffer from severe menstrual cramps and dysmenorrhea 
[132].   
Derman et al., (2004) investigated the frequency of premenstrual syndrome 
(PMS) associated symptoms and effects of nutrition on PMS in adolescent girls. 
Patients and methods: One hundred and seventy-one adolescent girls who had 
menstrual cycles were included in this study. They were given a questionnaire on 
criteria for PMS, dysmenorrhea and regularity of menstrual cycle. Modified 
Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria were 
used for the diagnosis of PMS. We also investigated which nutritional 
supplements affect the PMS-associated symptoms and signs. Results: One hundred 
and five adolescent girls out of 171 (61.4%) met DSM-IV criteria for PMS. There 
was an association between dysmenorrhea and PMS in 60 (57.1%). Half of the 
girls, i.e. 52 (49.5%) had mild, 39 (37.1%) had moderate and 14 (13.4%) had 
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severe PMS. The most common symptom of PMS was negative affect particularly 
in the form of stress (87.6%) and nervousness (87.6%). There was a statistically 
significant negative relationship between milk consumption and the following: 
abdominal bloating, cramps, craving for some foods and increased appetite. 
Conclusion: PMS and dysmenorrhea are frequently overlapping. We also found 
that PMS is associated with dietary habits [133]. 
Smith and Thomas (1996) conducted a study with the purpose to examine 
differences in locus of control and anger in college women with and without 
premenstrual syndrome (PMS). One hundred thirty-seven female undergraduates 
completed a biographical questionnaire, the Rotter Internal External Locus of 
Control (I-E) Scale, the Spielberger State Trait Anger Scale (STAS), the 
Framingham Anger Scale (FAS), and a women's health questionnaire. After 65 
women who had had children or used hormonally based contraceptives or 
psychotropic medications were excluded, the remaining subjects were placed into 
a PMS (n = 48) or a non-PMS group (n = 24) according to whether they met 
DSM-IV criteria for Premenstrual Dysphoric Disorder (PMDD). After debriefing 
the sample, the women were asked if they believed they had PMS. Results of the 
study showed no significant differences between groups in locus of control or 
anger. Out of the 72 subjects in the final analysis, 64 (89%) believed they had 
PMS, and only 8 (or 11%) believed they did not. Self-diagnosis was not always 
correct; 16 (22%) of the women who believed they had PMS did not meet the 
DSM-IV criteria for the disorder. The DSM-IV criteria may need further 
refinement and validation [134].  
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McLean and Barr (2003) characterized associations of restraint with 
selected physical, lifestyle, personality and menstrual cycle characteristics in 
female university students. The survey instrument, distributed to 1350 women, 
included standardized questionnaires (Three-Factor Eating Questionnaire, 
Perceived Stress Scale and Rosenberg's Self-esteem Scale), and assessed weight 
and dieting history, exercise, lifestyle characteristics, menstrual cycle 
characteristics and whether participants were following vegetarian diets. Among 
the 596 respondents included in the analysis (44%), women with high (n=145), 
medium (n=262) or low (n=189) restraint had similar ages, heights and weights. 
Despite this, compared to women with low scores, those with high scores 
exercised more (4.6+/-5.3 vs. 3.2+/-3.5 h/wk), were more likely to be vegetarian 
(14.5 vs. 3.7%), have a history of eating disorders (13.7 vs. 1.2%), be currently 
trying to lose weight (80.3 vs. 15.3%), report irregular menstrual cycles (34.7 vs. 
17.0%), and have scores reflecting lower self-esteem and higher perceived stress. 
Menstrual irregularity was an independent predictor of restraint score, and 
restraint score was the only variable to differentiate women with regular and 
irregular menstrual cycles. We conclude that women with high restraint may use a 
combination of behavioral strategies for weight control, and differ from women 
with low restraint scores in personality characteristics and weight history. Some of 
these behaviors or characteristics may influence menstrual function [135]. 
The purpose of this research conducted by Houston et al., (2006) was to 
determine: (1) The prevalence of dysmenorrhea, premenstrual symptoms and other 
menstrual disorders among adolescents who receive their health care at an urban 
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adolescent health center; (2) The attitudes and expectations adolescents have 
relating to their menstrual period; and (3) The relationship between teens' attitudes 
and expectations regarding menses and actual menstrual-related morbidities such 
as school absenteeism. A 35-item, survey was administered to post-menarcheal 
adolescents ages 12-21 years. Descriptive analysis of the prevalence of the 
menstrual disorders was completed. Chi-square testing was used to compare the 
prevalence of menstrual-related morbidities with the level of adolescents' 
expectations regarding menstruation. 91.5% of the respondents were African-
American. Premenstrual syndrome (PMS) was the most prevalent reported 
menstrual disorder (84.3%) followed by dysmenorrhea (65%), abnormal cycle 
lengths (13.2%), and excessive uterine bleeding (8.6%). Only 2% of teens report 
receiving information about menstruation from their health care provider. 
Negative expectations regarding menstruation were associated with higher rates of 
school absenteeism and missed activities (P = 0.0790 and P = 0.0297 
respectively). PMS and dysmenorrhea are prevalent medical disorders among 
urban adolescents. Morbidities, including school absenteeism, are higher among 
those with negative period expectations. Since only 2% of teens received 
information regarding menstruation from their health care provider, it is 
imperative that health care providers increase their anticipatory guidance 
regarding normal menstruation [136].   
Premenstrual stress affects 75% of women of childbearing age and yoga 
has been found to be beneficial in many psycho-somatic disorders. Therefore, 
Kanojia et al., (2013) investigated the effect of integrated yoga on autonomic 
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parameters and psychological well-being during both pre and post phases of 
menstrual cycle in healthy young female subjects [137]. This investigation was a 
randomized control trial conducted in the Department of Physiology, Lady 
Hardinge Medical College, New Delhi, India. Fifty apparently healthy females in 
the age group of 18-20 years were randomized into two groups: Group I (n=25) 
consisted of subjects who practiced yoga 35-40 minutes per day, six times per 
week for the duration of three menstrual cycles. Training was given by qualified 
yoga instructor. Group II (n=25) subjects acted as controls. Following parameters 
were recorded at the beginning and after completion of three menstrual cycles in 
all the subjects: Height, weight (BW), Resting Heart Rate (HR), Resting Systolic 
(SBP) and Diastolic Blood Pressure (DBP), parasympathetic reactivity tests 
including Expiration Inspiration Ratio (E: I ratio) and 30:15 ratio, sympathetic 
reactivity tests including BP changes due to Isometric Hand Grip (IHG) exercise, 
and Cold Pressor Test (CPT). Assessment of psychological status was done by 
administering DIPAS (Defense Institute of Physiology and Allied Sciences) 
inventories of Anger self- report scale, Trait Anxiety, Sense of well-being and 
Depression scale. Intra-group comparison of physiological parameters was done 
by using paired 't' test, whereas intra-group comparison of non-parameteric data 
such as scores of anxiety, depression, anger and sense of well-being was done by 
Wilcoxon signed-rank test. Inter-group comparison of parameters was done by 
Students 't' test for parametric tests and Mann-Whitney 'U' test for non-parameteric 
tests. The results showed significantly higher BW, resting SBP, DBP, sympathetic 
activity and blunting of parasympathetic reactivity and also, significantly higher 
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scores of anger, depression, anxiety and decreased score of well-being in 
premenstrual phase as compared to postmenstrual phase in both the groups in 
initial cycle. There was significantly higher percentage decrease in BW, HR, SBP 
& DBP in yoga group as compared to control group in both the phases from initial 
to second and onwards between second and third menstrual cycle. Also, decrease 
in anger, depression and anxiety and increase in well-being score was significant 
in yoga group as compared to control group from initial to second and third cycle 
in premenstrual phase while the change was significant only in depression score in 
postmenstrual phase. In conclusion this study shows that  there was significant 
alteration of autonomic functions and psychological status in premenstrual phase 
when compared with postmenstrual phase in young healthy females. Also, regular 
practice of yoga has beneficial effects on both phases of menstrual cycle by 
bringing parasympatho-dominance and psychological well-being probably by 
balancing neuro-endocrinal axis. 
Woods et al., (1994) compared arousal levels and stress response across 
menstrual cycle phases in women with three perimenstrual symptom patterns. 
Women with low symptom severity (LS, N = 28), were compared with those with 
a premenstrual syndrome (PMS, N = 15) and premenstrual magnification (PMM, 
N = 19) pattern across post-menses and pre-menses phases. Each woman was 
assessed during relaxation and in response to mental task and symptom imaging 
stressors during a post-menses and pre-menses day. Results of baseline skin 
conductance (SCL), electromyogram (EMG), and finger temperature (T) 
demonstrated arousal pre-menses in women with the PMS pattern, but not in 
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women with the LS pattern. In addition, women with the PMS pattern experienced 
increased EMG and SCL response to stressors pre-menses. Women with the PMM 
pattern experienced a rise in finger temperature pre-menses, opposite the pattern of 
the women with LS or PMS. These results support development of symptom 
management strategies to reduce arousal and modulate stress response for women 
with PMS who seek help for their symptoms. In addition, the difference in arousal 
and stress response observed in women with PMS and PMM support development 
of different symptom management strategies for these two groups of women 
[138]. 
Jang and Lee (2004) assessed the effects of qi therapy on premenstrual 
symptoms in women with premenstrual syndrome (PMS). Thirtysix (36) college 
women with symptoms of PMS were selected for this investigation. After 2 
months of screening, subjects with PMS were randomized to receive real qi 
therapy (18 subjects) or placebo (18 subjects). The subjects were informed that 
they would receive one of two types of treatment. They did not know which 
treatment they received. Each intervention was performed eight times during the 
second and third cycles with subjects completing a PMS diary. There were 
significant improvements in the symptoms of negative feeling, pain, water 
retention, and total PMS symptoms in subjects receiving qi therapy compared to 
placebo controls. Qi therapy may be an effective complementary therapy for 
managing the symptoms of PMS [139].  
Nisar et al., conducted a observational study (2008) to determine the 
frequency and severity of Premenstrual Syndrome (PMS) in medical college 
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students and to evaluate the impact of the condition on the quality of life and find 
out the associated risk factors. This study was conducted at Isra University 
Hospital, Hyderabad, Sindh, Pakistan, from August to December 2006. Unmarried 
medical students aged 18-25 years with regular menstrual period for the last 06 
months were recruited by convenience sampling. PMS related data was collected 
on daily record of severity of problems (DRSP) for two prospective cycles. 
Health-related quality of life data was collected on medical outcome study Short 
Form 36 (Sf - 36) after taking informed consent from participants. Descriptive and 
inferential analysis was done by two-tailed t-test and multivariate logistic 
regression analysis. Study participants (n=172) had mean age of 21.2 + 1.9 years. 
Eighty-nine (51%) girls met the criteria for PMS recording to ICD - 10, among 
them, 53 (59.5%) had mild PMS, 26 (29.2%) had moderate and 10 (11.2%) had 
severe PMS. Ten (5.8%) girls were found to have Premenstrual Dysphoric 
Disorder (PMDD) according to DSM - IV criteria. The order of frequency of 
symptoms were anger, irritability, anxiety, tiredness, difficult concentration, mood 
swings and physical symptoms like breast tenderness and general body discomfort 
with great impairment in social life / activities and work efficiency/productivity. 
Dysmenorrhea (p=0.003) and family history of premenstrual syndrome (p < 0.001) 
were significantly associated with premenstrual syndrome on univariate and 
multivariate analysis. Sf - 36 score on Mental Component Summary (MCS) and 
Physical Component Summary (PCS) were significantly lower in the affected 
group. Premenstrual syndrome is a common problem in young girls which 
adversely affects their educational performance and emotional well-being. 
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Strategies should be adopted for detection and management of PMS in young girls 
[140].  
Tolossa and Bekele (2014) assessed the prevalence, impacts and medical 
managements of PMS on female medical students of Mekelle University College 
of Health Sciences. A cross-sectional study was conducted among systematically 
selected female students of Mekelle University College of Health Sciences, 
Mekelle town, northern Ethiopia from March to April 2013. A structured and 
pretested self-administered questionnaire was employed for data collection. The 
collected data were analyzed using the Statistical Package for the Social Sciences, 
SPSS Inc., Chicago, IL (SPSS version 16). The criteria proposed by the Diagnostic 
and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV 
TR) were used to diagnose PMS. From the total population size of 608; a sample 
size of 258 was drawn. Age of the study participants ranged from 18 to 25 years, 
with mean age of 20.86 ± 1.913 years. Among the participants, 144(83.2%) have 
had at least one PM symptoms with their menstrual period. The prevalence of 
PMS according to DSM-IV was 37.0%. About 49(28.3%) reported frequent class 
missing, 17(9.8%) exam missing, 14(8.1%) low grade scoring and 3(1.7%) of 
them reported withdrawal from their learning associated with their PMS. Only 
83(48.0%) participants sought medical treatment for their PMS. The treatment 
modalities used were pain killers, 63(36.4%), hot drinks like coffee and tea, 
13(7.5%), and massage therapy and exercise, 7(4.0%). Binary logistic regression 
analysis revealed average length of one cycle of menstruation (COR = 0.20(0.070-
0.569) and academic performance impairment (AOR = 0.345(0.183-0.653) were 
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significantly associated with the diagnosis of PMS and use of PMS treatments 
respectively. The study revealed a high prevalence and negative impact of PMS on 
students of Mekelle University. Therefore, health education, appropriate medical 
treatment and counseling services, as part of the overall health service, should be 
availed and provided to affected women [141].  
Premenstrual syndrome (PMS) is a distressing group of symptoms related 
to menstrual cycle during reproductive age. Its substantial burden on daily 
function and quality of life, particularly on mental aspects, was to the impetus for 
this study with the aim of determining the effectiveness of a psycho-educational 
package on premenstrual syndrome and related symptoms. In a randomized 
clinical trial, conducted by Taghizadeh (2013) randomized 123 (17-19-year-old) 
adolescent girls with PMS to psychoeducational intervention (including 62 
subjects) and control (including 61) groups. The participants completed a 
demographic questionnaire, premenstrual syndrome symptom daily record scale 
and the Symptom Checklist-90-Revised (SCL-90-R). A paired and two 
independent samples test and chi-squared test were used for analysing data using 
SPSS statistical package. At the end of the study there was statistically significant 
decrease in severity of total PMS in intervention compared with control group (P < 
0.001). Also, a significant difference in somatization, anxiety and hostility was 
observed between two groups (P < 0.05). However, depression marginally 
decreased (P < 0.1) in intervention group, and interpersonal sensitivity was not 
statistically different between intervention and control groups. Intervention 
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alleviated the severity of PMS and related somatization, anxiety and hostility, yet 
it could not change the severity of depression and interpersonal sensitivity [142].  
A review study was done by Stevinson Clare (2001) to find out whether 
there are enough evidences related to the effectiveness of alternative or 
complementary treatment in the form of clinical trials. Seven databases were 
searched in order to locate the trials and list of references were checked. In the 
review, randomized controlled studies that studied alternative/complementary 
treatments with respect to PMS were included. These studies were published in 
peer-reviewed journals. 27 studies which researched the effect of herbal medicine, 
dietary supplements, homeopathy, relaxation, reflexology, massage, biofeedback, 
and chiropractic were included in this review. In spite of some supportive findings, 
most of the evidences were not satisfactory for alternative and complementary 
therapies as there were many methodological restrictions. Based on these findings, 
it was concluded that alternative or complementary cannot be given for treatment 
of PMS [143].        
In another study Schneider et al., (1999) studied menstrual function and 
premenstrual symptoms in a structured, rigorous military environment. A survey 
about high school menstrual and premenstrual function, and the Premenstrual 
Assessment Form (PAF), were completed by all 158 freshman female Cadets in 
July 1991. In May 1992, 83 participants completed a survey assessing menstrual 
and premenstrual symptoms, including interference with activities during the year. 
Participants reported menstrual patterns and premenstrual symptoms in high 
school similar to other females their age. Most (62%) predicted a change in 
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menstruation at the USMA, half were worried that physical symptoms would 
interfere with activities, one-fourth were worried that premenstrual symptoms 
would interfere with activities, and one-fourth were worried that obtaining and 
changing menstrual materials would interfere with activities. Almost all 
respondents (91%) reported changes in menstruation during the year, most 
commonly less regular, less frequent, shorter, lighter, and less crampy periods. 
Menstrual and premenstrual symptoms interfered with physical activities (66.2%, 
61.4% respectively) more so than academic (50.6%, 45.7% respectively) or 
military activities (39.8%, 47.0% respectively). Female Cadets described 
significant difficulties with changing (62.6%), obtaining (51.8%), and disposing of 
(38.5%) menstrual materials. The data demonstrate major changes in menstrual 
function in over 90% of female Cadets; a significant perceived impact of 
menstrual and premenstrual symptoms on academic, physical, and military 
activities; and difficulties in obtaining, changing, and disposing of menstrual 
materials in a military setting. These findings have implications for females in the 
military, as well as for young women generally [144].  
Yamamoto et al., (2009) examined the relationship between menses 
associated health problems of women, such as premenstrual symptoms, menstrual 
pain and irregular menstrual cycles, and psychosocial stress. A cross-sectional 
study was conducted among Japanese college students, measuring psychosocial 
stress levels by means of IMPS (The Inventory to Measure Psychosocial Stress). A 
total of 264 female students (mean age 19.4 years), who were invited to participate 
in the study in October 2007, completed the questionnaire, which dealt with 
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anthropometric data, lifestyle, menstrual history, and menstrual health status. 
Forty-three students were excluded due to missing data, and the remaining 221 
were analyzed. The proportions of students who reported premenstrual symptoms, 
menstrual pain, and the experience of irregular menstrual cycles were 79%, 79%, 
and 63%, respectively. Students who reported premenstrual symptoms, menstrual 
pain, and the experience of irregular menstrual cycles had higher stress scores than 
those who did not. Multiple logistic regression analyses were used to identify 
independent factors associated with having premenstrual symptoms, menstrual 
pain, and the experience of irregular menstrual cycles. Stress score, heavy 
menstrual flow, and menstrual pain were significant predictors for premenstrual 
symptoms, while age at menarche and having premenstrual symptoms were 
significant predictors for menstrual pain. Both stress score and body mass index 
were found to be significant predictors for having experienced irregular menstrual 
cycles. The results suggest that psychosocial stress is independently associated 
with premenstrual symptoms and the experience of irregular menstrual cycles 
among college students, implying that changes in the functional potentiality of 
women as a result of stress are related with changes in their menstrual function 
[145].  
Premenstrual syndrome is a term which includes a broad group of 
emotional, behavioral and physical symptoms that occur for several days before 
menses and subside following the menstrual period. Many women experience 
premenstrual syndrome symptoms, particularly physical ones such as breast 
tenderness and swelling. Approximately 5-10% women suffer from severe 
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premenstrual syndrome and another 30-40% have moderate symptoms. 
Premenstrual syndrome continues to be an unsolved problem. In this study, Ozisik 
et al., (2005) evaluated 24 premenstrual syndrome patients and 20 healthy women 
in the control group. The ages of the women were 2234 years (mean +/- SD: 25+/-
3) for the premenstrual syndrome group and 2334 (25+/-3) for the control group 
[146]. The sympathetic skin response was recorded from the palms, soles and 
genital regions by using electrical stimuli to the median nerve at the wrist. The 
sympathetic skin response was recorded twice, in the follicular and late luteal 
phases of menstruation. The follicular and late luteal phase sympathetic skin 
response of the two groups were compared. The amplitudes and latency values of 
the late luteal and follicular phase sympathetic skin response from the 
premenstrual syndrome group and control group women were statistically similar. 
Further, there was not any latency or amplitude difference in the sympathetic skin 
response obtained from the three regions of the premenstrual syndrome patients 
and the control group. The investigators checked sympathetic skin response in the 
symptomatic (late luteal phase) and asymptomatic (follicular phase) periods of 
patients with premenstrual syndrome, a disorder known to have many autonomic 
symptoms, to determine whether there was sudomotor sympathetic involvement. 
The results of selected PMS patients indicate at the very least that there is no 
difference with the control subjects as regards peripheral sudomotor 
functions[146].  
Kuczmierczyk and Adams (1986) compared eleven women with a clinical 
diagnosis of premenstrual syndrome (PMS) and ten non-PMS control women on 
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physiological measures in the intermenstrual and premenstrual phases of their 
menstrual cycle. Heart rate (HR) and skin conductance level (SCL) were 
monitored during baseline conditions and in response to a stressful laboratory 
procedure. Analyses for HR revealed a three-way interaction (groups X phase X 
tests) which approached significance indicating that the PMS group was generally 
lower during the intermenstrual testing but was higher in the premenstrual phase. 
No significant differences were observed on behavioral measures (pain threshold, 
pain tolerance) between the groups. Pain intensity ratings were found to be overall 
higher in the PMS group irrespective of menstrual cycle phase. The role of 
cognitive-perceptual processes is discussed in the context of the acquisition and 
maintenance of PMS symptomatology [147].  
To investigate the comorbidity of premenstrual syndrome (PMS) and 
menstrual migraine, Facchinetti et al., (1993) administered the Menstrual Distress 
Questionnaire (MDQ) for two consecutive menstrual cycles to 22 patients with 
menstrual migraine, 12 cases with migraine without aura and 15 patients with 
PMS. MDQ scores varied throughout the menstrual cycle in each patient group, 
the wider changes being shown by patients with PMS. Fourteen menstrual 
migraine patients and 4 migraine without aura patients achieved diagnostic criteria 
for PMS over two menstrual cycles. In these patients MDQ scores did not differ 
from PMS sufferers at any stage of the menstrual cycle. The premenstrual increase 
of each cluster of PMS symptoms was identical in menstrual migraine and PMS 
subjects with the exception of negative affect. It was suggested that PMS 
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symptoms should be taken into account in the IHS diagnostic criteria for menstrual 
migraine [148]. 
Palmero and Choliz (1991) conducted a study on 64 undergraduate female 
students. During 3 consecutive months women answered a chart of daily report of 
symptoms, and finally, two groups were formed: women with premenstrual 
symptoms (PMS group) and women without premenstrual symptoms (NPMS 
group). Heart rates (HR) at rest were recorded throughout premenstrual, 
menstrual, postmenstrual, and ovulatory phases. In the premenstrual phase, PMS 
group showed significantly higher resting HR levels than NPMS group. With 
regard to resting HR levels across the four phases studied, significant differences 
within PMS group were observed. The results of this study are discussed from a 
psychophysiological point of view [149].  
Groer and Ohnesorge (1993) investigated the effects of a program of 
relaxation and specific guided imagery on menstrual-cycle length and 
premenstrual distress. Thirty healthy college women with regular menstrual cycles 
were studied for 6 months. The subjects completed the Menstrual Distress 
Questionnaire (MDQ) at the beginning and end of the study and recorded their 
menstrual cycles for 3 months on an investigator-developed calendar recording 
sheet. Subjects were then given an audiotape with a progressive muscle relaxation 
exercise followed by guided imagery with a suggestive message focusing on 
lengthening the menstrual cycle and delaying the onset of menstrual bleeding. The 
15 subjects who completed the entire study had significant increases in cycle 
lengths during the 3 months of imagery. The total premenstrual distress scores also 
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declined significantly, as did the subscales measuring behavior and negative 
affect. This study provides preliminary evidence that menstrual-cycle rhythmicity 
and premenstrual distress are amenable to the mind-body intervention of guided 
imagery and suggests that further investigation of this phenomena with larger 
sample size and careful controls for confounding variables be conducted [150]. 
The mood changes surrounding menstrual cycle mainly during luteal phase, 
known as premenstrual syndrome, have been described as early as the time of the 
ancient Greeks. Jasuja et al., (2014) studied psychological symptoms of anxiety 
and depression by using Beck Depression Inventory (BDI-II) and State Trait 
Anxiety Inventory (STAI). The main aim of this investigation was to study the 
psychological parameters and effects of PMR on females with premenstrual 
syndrome. Sixty participants aged between 18 and 40 years, volunteered for this 
study. Relaxation technique, PMR was given to the study group (Group A, Mean 
age 24.13±5.69) for one month and control group (Group B, Mean age 
28.96±9.42) was evaluated without any intervention. Paired students t test. Alpha 
error was set at 1% level. PMR Group A showed significant decrease in Both BDI 
II and STAI scores (p<0.001), showing benefits of relaxation in reducing anxiety 
and depression. The study concluded that PMR helps to alleviate symptoms of 
premenstrual syndrome and decreases anxiety and depression as shown by 
changes in scores of both questionnaires [151].  
An education program was developed by Chau and Chang (1999) and 
tested the efficacy in order to decrease the severe symptoms associated with PMS 
i.e. premenstrual syndrome and increasing the knowledge related to premenstrual 
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syndrome. The study participants were recruited from four schools aged 14-18 
years in Hong Kong. 94 adolescent girls were assigned to either experimental 
group or control group. PMS knowledge questionnaire was administered to the 
experimental group immediately after giving the education program. Abraham’s 
Menstrual Symptom Questionnaire’s translated version was administered in order 
to measure total premenstrual syndrome scores. Whereas no such significant 
changes were found in the control group, suggesting that probably the education 
program was the reason for the decrease in premenstrual syndrome in young girls 
of experimental group [152].   
Tabassum et al., (2005) conducted an observational study (2005) to find out 
the frequency of premenstrual syndrome (PMS) in young college girls and to 
describe the severity of emotional, physical and behavioural symptoms. The study 
was conducted at the Khyber Medical College, Peshawar by convenient sampling 
on 384 young girls. Data was collected over two cycles by filling a 29 items 
shortened premenstrual assessment form based on Moos Menstrual Distress 
Questionnaire after taking consent from medical students. Results were given 
according to both criteria i.e. ICD-10 and DSM-IV. The frequency of premenstrual 
syndrome was 53% according to ICD-10 criteria, among which 42% was mild, 
18.2% moderate and 31.7% severe. A total of 64 girls (18.2%) met the DSM-IV 
criteria for severe PMS or Premenstrual Dysphoric disorder (PMDD). The order of 
frequency of symptoms occurring in PMS was general body discomfort, anxiety, 
backache,fatigue and depression. Most frequently reported symptoms in PMDD 
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group were anger, anxiety, stress, depression, fatigue and general body discomfort 
[153]. 
Frackiewicz and Shiovitz (2001) reviewed premenstrual disorders, their 
varied symptoms, possible etiology, and treatment options. Data Sources: 
Published articles identified through MEDLINE (1966-2001) using the search 
terms premenstrual syndrome (PMS) and premenstrual dysphoric disorder 
(PMDD) and the additional terms treatment and etiology. Additional references 
were identified from the bibliographies of the retrieved articles. PMS refers to a 
group of menstrually related disorders that are estimated to affect up to 40% of 
women of childbearing age. The varied symptoms of PMS include mood swings, 
tension, anger, irritability, headache, bloating, and increased appetite with food 
cravings. PMS symptoms occur during the luteal phase of the menstrual cycle and 
remit with the onset of menstruation or shortly afterward. Approximately 5% of 
women with PMS suffer from PMDD, a more disabling and severe form of PMS 
in which mood symptoms predominate. Because no tests can confirm PMS or 
PMDD, the diagnosis should be made on the basis of a patient-completed daily 
symptom calendar and the exclusion of other medical disorders. The causes of 
PMS and PMDD are uncertain, but are likely associated with aberrant responses to 
normal hormonal fluctuations during the menstrual cycle. For most women, 
symptoms can be relieved or reduced through lifestyle interventions, such as 
dietary changes and exercise, and drug therapy with hormonal or psychotropic 
agents. For PMDD, selective serotonin reuptake inhibitors have recently emerged 
as first-line therapy. Certain dietary supplements, including calcium, also may be 
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an option for some women. PMS and PMDD are complex but highly treatable 
disorders. Pharmacists can improve the recognition and management of these 
common conditions by providing patient education on premenstrual symptoms and 
counseling women on lifestyle interventions and pharmacotherapy to relieve their 
discomfort [154]. 
According to Abraham (1983) have reported 150 symptoms under the 
heading of premenstrual syndrome, in that more than 97% of women were 
experiences at least one of the symptoms. One of the important areas related to 
menstrual cycle is premenstrual syndrome that is related to the first part of 
menstrual cycle started after ovulation, increased its intensity during 3 to 5 days 
prior to the menstruation to first day of menstrual flow related to her physical 
change, mood, behavior and changes in social adjustment.   
Anandhalakshmi, et al. (2011) SRM medical college hospital and research 
centre, conducted a cross sectional study to assess the prevalence of premenstrual 
syndrome among young college students. The study sample was 300 students, in 
that 96% of the students had at least one symptom of premenstrual syndrome and 
the prevalence of premenstrual syndrome was 67%. The finding shows that 
association between body mass index and premenstrual syndrome, they concluded 
that prevalence of premenstrual syndrome common in college students [155.]. 
Anderson and Johnson (2005) conducted a randomized controlled study to 
identify the use of complementary and alternative therapies for obstetrics and 
gynecological treatment and health promotion. Fifty four articles assessing a 
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variety of health modalities meeting the criteria were included. The study 
concluded that Complementary and Alternative medicine interventions have 
evidence of effectiveness for use in obstetrics and gynecological problems [156.]. 
Wang et al. (2012) investigated the prevalence of premenstrual syndrome 
and premenstrual dysphoric disorder among the age group of 18-45 years. For 
those who were consistent with premenstrual syndrome diagnostic criteria, the 
daily record of severity of problems assessed over two months. Participants were 
then categorized as having no perceived symptoms, mild premenstrual syndrome, 
and moderate premenstrual syndrome. Among them irritability 91%, breast 
tenderness 78%, depression 68 %, abdominal bloating 64% [157]. 
In the year 2012 Kitamura conducted a study to determine the relationship 
between premenstrual syndrome among adolescent girls, a total of 1,431 high 
school students were assessed. Out of them, 71.3% were classified with moderate 
to severe premenstrual syndrome and 30.2% with premenstrual dysphoric disorder 
and also 85% of the students had dysmenorrhoea. The rates of prevalence of 
premenstrual dysphoric disorder and moderate to severe premenstrual syndrome 
were increased according to the severity of dysmenorrhea [158].  
A cross sectional study to assess the prevalence of premenstrual syndrome 
was conducted by Joshi et al. (2011), 107 samples were selected between the age 
group of 18-30 years by using simple random method, the findings shows that 26 
(24.3%) persons did not reported any symptoms and 81 (75.7%) were reported the 
symptoms of premenstrual syndrome. Mastalgia was the most common symptom 
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(50.5%), followed by mood changes (46.7%), depression (7.5%) and anger attacks 
(6.5%) [159].  
In Surya Fertility centre, Bhakti (2011) conducted a descriptive study to 
assess the prevalence of premenstrual syndrome among the reproductive age 
group. Among them 80% of them had mild to moderate premenstrual syndrome, it 
is estimated by including all women who experience any physical or emotional 
symptoms prior to menstruation. In that 30-40% of them had severe symptoms. 
Only 10% of them had more severe symptoms [160.].  
Sharma et al. (2011) conducted a study to assess the type and frequency of 
problem related to menstruation in Maulana Azad medical college, New Delhi, 
198 students had been studied. Data was collected by personal interviews using a 
pre-tested, semi structured questionnaire. Results showed that, dysmenorrhea 
(67.2%) was one of the problems and 63.1% had one or the other symptom of 
premenstrual syndrome. Daily routine of 60% of girl, was affected due to 
prolonged bed rest, missed social activities, disturbed sleep and decreased 
appetite. Study concluded that students had high prevalence of premenstrual 
syndrome and they need counseling services, relevant information on possible 
treatment options [161]. 
A cross sectional descriptive study was conducted to assess the prevalence 
and severity of premenstrual syndrome, with the objectives to rule out the 
problems related to menstruation in the last three cycles. Study was conducted in 
three medical collages at different states of India (Jagadalpur, Orissa and 
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madyapradesh). 107 female medical students were randomly chosen for this study. 
Results showed that the mean age at menarche was 12 years and premenstrual 
syndrome is the most common problem. In this study 6.32%, 30.37% and 63.2.9% 
participants were suffering from severe, moderate and mild level of premenstrual 
syndrome, respectively. 
A descriptive study was conducted to determine the frequency and severity 
of Premenstrual Syndrome in medical college students to evaluate the impact of 
the condition on the quality of life and to find out the associated risk factors. 
Unmarried medical students aged between 18-25 years with regular menstrual 
period for the last six months were recruited by convenience sampling. Study 
participants (n=172) had mean age of 21 years. 89 (51%) of the girls met the 
criteria for Premenstrual syndrome, among them, 53 (59.5%) had mild symptoms, 
26 (29.2%) had moderate symptoms and 10 (11.2%) had severe symptoms.10 
(5.8%) of the girls were found to have Premenstrual Dysphoric Disorder. 
Dysmenorrhea (p < 0.003) and family history of premenstrual syndrome (p < 
0.001) were significantly associated with premenstrual syndrome on univariate 
and multivariate analysis.  
In the year (2009) cross-sectional study was carried out among college 
students of Zahedan University (Iran), aged between 18-27 years. Overall 300 
participants were asked to complete an anonymous questionnaire assessing 
premenstrual symptoms. Out of the 300 participants, 98.2% reported at least one 
symptom. Most common symptoms were feeling of tiredness or lethargy (84%), 
depressed mood (72.3%), sudden feeling of sadness or tearfulness (70.3%), 
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anxiety (70%), backache (69%) and sleep problems (66%). The severity of 
symptoms was significantly higher for the younger women (18-24 years) 
compared to the older women (25-27 years). Preventive and treatment strategies 
for premenstrual syndrome are highly recommended. According to studies 
menstrual problems are common among young girls. 
Thakra et al. (2008) conducted a study to find out the types and frequency 
of problems related to menstruation in adolescent girls and the effect of these 
problems on daily routine. 198 adolescent girls have been studied between the age 
group of 13-19 years. Data was collected by personal interviews on a pre-tested, 
semi-structured questionnaire. The questions covered menstrual problems. 
Dysmenorrhoea was the commonest problem is around 67% and 63.1% of the 
girls had one or the other symptoms of Pre-menstrual syndrome. Other related 
problems were present in 55% of study subjects. Among them 60% of girls were 
affected with daily routine due to prolonged bed rest, missed social 
activities/commitments, disturbed sleep and decreased appetite. 17% of them had 
absenteeism to school and 25% of them had abstained from work [162].   
The study findings affirm the fact that premenstrual syndrome profoundly 
affects the academic activities of young female medical students [163]. 
A journal on alternative and complimentary medicine (2010), Kathryn, 
conducted a cross sectional study to explore the effect of aromatherapy on 
premenstrual syndrome among college students. The study was a randomized 
placebo-control trail. The sample size was 67 college students. The visual 
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analogue scale was used to assess their pain level with a verbal multidimensional 
scoring system. The menstrual cramps were   significantly lowered in the 
aromatherapy group than in the other groups at both post-test points. The findings 
suggest that aromatherapy using topically applied lavender, clary sage, rose is 
effective in decreasing the severity of menstrual cramps. Aromatherapy can be 
offered as part of the nursing care to women experiencing menstrual cramps [164]. 
A study was conducted by Carroll (2011) among 80 students suffering from 
premenstrual syndrome. The students were randomly divided into two groups and 
received, either 10 drops of citrus essence or placebo drops, three times a day 
during the luteal phase for two cycles. The group on citrus essence witnessed a 
significant reduction of 46.08% in the symptoms compared to the group on 
placebo 14.21%, (p<0.001). After the intervention, there were also significant 
decreases in the severity of physical and psychological symptoms in both citrus 
essence respectively, 24.3% and 21.78% and placebo groups respectively, 2.07% 
and 9.21%, (p<0.001). The study showed that citrus essence could reduce the 
severity of premenstrual syndrome. The essence is suggested to be taken during 
the luteal phase in two consecutive cycles [165].  
In the year 2010 Brush et al. conducted the study to evaluate the 
effectiveness of primrose oil on management of premenstrual syndrome, the 
sample size was 68 and they received 1-2gms of prime rose oil for 3 days before 
the onset of premenstrual symptoms until the first day of menstruation, based on 
self report scale the researcher concluded that among them 61% of them had 
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complete relief of premenstrual symptoms, 16% of them had partial relief of 
symptoms [166].  
Dante (2010) conducted a meta analytical study to find out the use of 
natural oils for the management of premenstrual syndrome, the findings reported 
that vitex agnus castus and the evening primrose oil will be more effective in the 
management of premenstrual symptoms [167].   
A study was conducted to evaluate the therapeutic effectiveness of evening 
primrose oil in the relief of 10 symptoms associated with premenstrual syndrome 
was studied in 38 women,. The prospective trial was randomized; double-blind 
and placebo controlled and was crossed over after three cycles. Although the result 
showed an improvement in symptoms of premenstrual syndrome during the trial, 
no significant difference in the scoring between the active and placebo groups 
were found over six cycles. No carry over effect of active medication was 
observed, the beneficial effect on all symptoms was rapid, the scoring decreasing 
in the first cycle but increasing slightly at the change-over period after the third 
cycle, irrespective of whether the active and placebo medication was next given. 
These findings indicate that the improvement by the women with moderate 
premenstrual syndrome was slowly a placebo effect. According to the report of 
George in the year 2007, more than 85% of the person will be getting relief of 
premenstrual syndrome with primrose oil massage. He selected the sample of 100 
college students with premenstrual syndrome and the intervention given to the 
students with lavender oil massage for the duration of 15-20 minutes for three 
days [168].   
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Sampalis (2006) conducted a study to evaluate the effectiveness of Neptune 
Krill Oil for the management of premenstrual syndrome and dysmenorrhoea and 
to compare the effectiveness of Neptune krill oil for the management of 
premenstrual syndrome and dysmenorrhoea with that of omega-3 fish oil. 
Treatment period of three months with either Neptune krill oil or omega-3 fish oil. 
In 70 patients with complete data, a statistically significant improvement was 
demonstrated among baseline, intermittent, and final evaluations in the self 
assessment questionnaire (p < 0.001) within the Neptune krill oil group as well as 
between-group comparison to fish oil, after three cycles or 45 and 90 days of 
treatment. Data analysis showed that Neptune Krill Oil can significantly reduce 
dysmenorrhoea and the emotional symptoms of premenstrual syndrome and is 
shown to be significantly more effective for the complete management of 
premenstrual symptoms compared to omega-3 fish oil [169]. 
Kim et al. (2006) conducted a cross sectional study to explore the effect of 
aromatherapy on premenstrual syndrome among college students. The study was a 
randomized placebo-control trail. The sample size was 67 college students. The 
visual analogue scale was used to assess their pain level with a verbal 
multidimensional scoring system. The menstrual cramps were   significantly 
lowered in the aromatherapy group than in the other groups at both post -test 
points. The findings suggest that aromatherapy using topically applied lavender, 
clay sage, rose is effective in decreasing the severity of menstrual cramps. 
Aromatherapy can be offered as part of the nursing care to women experiencing 
menstrual cramps.  The study consisted of a double-blind, three-group 
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experimental pre-test and post-test design, and the results indicated that menstrual 
cramps were significantly lowered in the aromatherapy group than in the other two 
groups after the intervention [170].  
A randomized placebo-controlled clinical trial on college students to assess 
the effect of aromatherapy upon menstrual cramps by Han et al. ( 2012). The 
students were randomized into three groups: (1) an experimental group who 
received aromatherapy, (2) a placebo group, and (3) a control group. 
Aromatherapy was applied topically to the experimental group in the form of an 
abdominal massage using two drops of clary sage and one drop of rose in 5 cc of 
almond oil. The placebo group received the same treatment but with almond oil 
only. The menstrual cramps were significantly lowered in the aromatherapy group 
then in the other two groups at both post-test time points [171]. 
Wang et al. (2012) conducted a cross sectional study to investigate the 
effect of self-aromatherapy massage on menstrual pain and anxiety among staff 
nurses. The subjects were 63 female nurses who rated their menstrual pain >5 on a 
10-point visual analogue scale. Subjects were non-randomly allocated into three 
groups. Menstrual pain and anxiety levels were assessed using a visual analogue 
scale, and we assessed the menstrual pain 4 times during a short time period. The 
menstrual pain was significantly lower in the aromatherapy group than in the other 
two groups after 24 hours. Using multiple regression analysis, the use of 
aromatherapy was found to be associated with the changes in premenstrual 
symptoms [172].   
64 
 
In the year 2012 Taavoni conducted a randomized placebo-controlled 
clinical trial in a menopausal clinic at a gynecology hospital in Tehran. The study 
population comprised of 90 women who were assigned to an aromatherapy 
massage group, a placebo massage group, or a control group. Each participant in 
the aromatherapy massage group received 30-minute aromatherapy treatment 
sessions twice a week for 4 weeks with aroma oil, whereas participants in the 
placebo massage group received the same treatment with plain oil. When the 
aromatherapy massage and the placebo massage groups were compared, the 
menopausal score for the aromatherapy massage group was found to be 
significantly lower (P < 0.001) than for the placebo group. The results of the study 
demonstrate that both the placebo massage and aromatherapy massage were 
effective in reducing menopausal symptoms. However, aromatherapy massage 
was more effective than placebo massage [173].   
Brent (2011) investigated the alleviating effects of aromatherapy massage 
and acetaminophen on menstrual pain among students subjects were divided into 
two groups: the aromatherapy massage group with the sample size of (n=32) and 
the acetaminophen group with the sample size of (n=32).  Aromatherapy massage 
was performed on subjects in the treatment group. The abdomen was massaged 
once using clary sage, marjoram, cinnamon, ginger, and geranium in a base of 
almond oil. The level of menstrual pain was assessed using a visual analogue scale 
at baseline and twenty-four hours afterward. The reduction of menstrual pain was 
significantly higher in the aromatherapy group than in the acetaminophen group. 
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These finding suggest that aromatherapy massage provide effective treatment for 
menstrual pain among the students [174].   
A randomized placebo- controlled clinical trial was conducted in Korea 
with the objective to explore the effect of aromatherapy on menstrual cramps and 
symptoms of dysmenorrhoea. The subjects were 67 college students. Subjects 
were randomized into three groups, an experimental group (n=25) who received 
aroma therapy, a placebo group (n=20) and  a control group (n=22) Aromatherapy 
was applied topically to the experimental group in the form of an abdominal 
massage using two drops of lavender, one drop of clary sage and one drop of rose 
in 5cc almond oil. The placebo group almond oil only and the control group 
received no treatment. The menstrual cramps were assessed using a visual 
analogue scale. Menstrual cramps were significantly lowered in the aromatherapy 
group than in the other two groups [175].  
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4. MATERIALS AND METHODS 
4.1 Subjects: 
A total of 60 women volunteers who met the inclusion criteria with ages ranging 
between 18 to 35 years old participated in the study. 
4.2 Source of subjects: 
The study subject were women volunteers recruited from general 
population, students, the out-patient and In-patient department of Government 
Yoga and Naturopathy Medical College & hospital, Arumbakkam, Chennai-106. 
The subjects underwent medical examinations and completed a standardized PSST 
Questionnaire before inclusion into the study. None of the women were pregnant 
or reported taking oral contraceptives to control the menstrual cycle, however 
pregnancy tests were not performed and regular menstrual cycles resumed every 
month in all the subjects. Olfactory function tests were performed on subjects to 
assure that none had anosmia. subjects were given two sets of three bottles- two 
held distilled water and the third contained essential oil and were asked to choose 
the correct response in both trials. 
4.3 Inclusion and Exclusion criteria: 
4.3.1 Inclusion criteria: 
The following inclusion criteria would be the basis for selecting the subjects: 
• Age group: between 18-35 years. 
• Women with premenstrual syndrome.  
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• Women who are not exposed to aromatherapy previously. 
• Women who are willing to give their consent. 
4.3.2 Exclusion criteria: 
Participants will be excluded if they have systemic issue. 
• Pre-menstrual dysphoric disorder. 
• Below 18 years and above 35 years.  
• Under medication. 
• Chronic illness. 
• Pregnancy and Lactation. 
• Recently hospitalized. 
4.4 Written Informed consent: 
Subjects who fulfilled inclusion criteria received an explanation of the 
nature and purpose of the study; to investigate soothing effects of plant fragrance 
on symptoms of premenstrual syndrome and rights as research subjects. We did 
not, however inform subjects of which fragrance we would use for the 
experiments. Informed consent form was administered in English. Adequate time 
was given to each subject to go through the information sheet and their queries 
were answered. Their right to withdraw from the study and the need for 
willingness to participate voluntarily in the study was explained. All the subjects 
expressed their willingness to participate in the study by giving a signed informed 
consent. (A sample information sheet and consent form is enclosed in Annexure). 
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4.5 Study design:  
Experimental study method. The total study duration of each patient is 3 
months. Initial screening will be done to select the patients meeting the 
requirements of inclusion criteria and selected patients will be allotted for 
intervention. 
4.6 Ethical clearance: 
Subjects who fulfilled the inclusion criteria were appraised about the 
purpose of the study and their rights as research subjects. Informed consent form 
was administered in local language i.e., Tamil and English as well. Adequate time 
was given to the participants to go thrugh the information sheet and their queries 
were answered. Their rights to withdraw anytime from the study and the need for 
willingness to participate voluntarily in the study were explained. All the subjects 
expressed their willingness to participate in the study by giving a signed informed 
consent. (A sample information sheet and consent form is enclosed as Annexure). 
Ethical clearance was obtained from the Institutional Ethical Committee prior to 
the start of the study and the approval for the same was granted. 
4.7 Allocation of Subjects: 
Subjects were randomly allocated in Study group (Aroma exposure group) 
and Placebo control group (Water exposure group) in 1:1 ratio. 70 Subjects were 
initially screened.60 subjects who met the inclusion and selection criteria were 
allocated in the study. Subjects were then randomly divided into 2 groups i.e., (n= 
30) Study group and (n= 30) Placebo control group using lottery method.
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4.8 Trial profile: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomization 
Study group, n=30 
( Aroma exposure ) 
Placebo Control group, n=30 
(Water exposure) 
 
Pre assessment -PMSS Pre assessment -PMSS 
 
Potential subjects will be 
screened based on PSST 
Questionnaire, n=70 
Clary sage oil inhalation through 
diffuser for 3 months thrice a week. 
Water exposure through 
diffuser for 3 months thrice a 
week 
Post 
 assessment 
Post 
assessment 
Statistical data analysis and results 
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4.9 Intervention 
4.9.1 Tools of Intervention: 
4.9.1.1 PSST: 
‘The Premenstrual Symptoms Screening tool’’ (PSST). The PSST 
reﬂects and ‘translates’ categorical DSM-IV criteria into a rating scale with 
degrees of severity. The results are in line with reported prevalence rates from 
several recent large prospective studies. We believe that the PSST applies a 
necessary degree of measure of severity and impact of premenstrual symptoms, 
establishes quickly if women qualify for PMDD, and is less time consuming 
and more practical than two cycles of prospective charting. This fast simple 
tool is an effective screening tool and an important starting point for further 
assessment. 
4.9.1.2 PMSS: 
Premenstrual syndrome scale (PMSS). The scale was to measure 
premenstrual symptoms, and validity and reliability analyses were performed. 
The premenstrual syndrome scale comprised 40 questions with three sub-scales 
(Physiological, Psychological and Behavioural symptoms). This 5-point Likert- 
type scale consisting of 40 items. The measurements on the scale are set 
according to the following scoring system: the response Never was scored as 
“1”, rarely as “2”, sometimes as “3”, very often as “4” and always as “5” 
points.  
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4.9.2 Study group: 
30 subjects were randomly selected and exposed to clary sage aroma 
nasal diffuser for 10 minutes thrice a week for three months. 
4.9.3 Procedure: 
This experiment used two kinds of aroma stimulation – Clary 
sage(Salvia sclerae) and water as a control.10 µl of clary sage essential oil or 
water were pipetted into a small cotton pad designed for a diffuser(Aroma care 
diffuser).Air flow from the diffuser was  placed near the subjects nostril using 
the diffusers 15 cm long circular cylinder fitted with a perforated funnel of 
diameter 3 cm for 10 minutes. The procedure was performed thrice a week for 
3 months i.e 36 sessions after which the PMSS was repeated. 
4.9.4 Placebo control group: 
30 subjects were randomly selected and exposed to water through 
diffuser for 10 minutes thrice a week for three months. 
4.9.5 Assessments: 
The pre-intervention and post-intervention assessments were collected 
using Premenstrual Syndrome Scale questionnaire (PMSS). This a 
standardized, self-administered 40 item questionnaire to assess physiological, 
psychological and behavioral symptoms. Each symptom was rated on five 
points ranging from never to always. These added raw scores were then 
converted to T scores according to PMSS manual. 
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4.9.6 Data collection: 
 The baseline data was collected during the first month. After 
randomization and respective interventions post intervention data was collected 
at the end of three months using self-reported PMSS. Data were organized in 
Microsoft Excel sheets (version 2010) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
73 
 
 5. RESULTS 
All 60 participants successfully completed the study. Premenstrual 
Syndrome Scale questionnaire (PMSS) was used to assess the difference 
before and after intervention. PMSS is a self-reported scale consisting and 
assessing 3 components- physiological, psychological and behavioural. The 
normality of distribution was measured using Shapiro-wilks test. Comparisons 
between groups was measured using Mann whitney U-test and within group 
was measured using Wilcoxon signed rank test. At baseline, the mean 
physiological, psychological and behavioural components of the 60 
participants were 65.07 (IQR 61, 69), 51.22 (IQR 48, 55.75) and 51.50 (IQR 
47.25, 56) respectively (Table 1).  Mean reduction in the physiological score 
was higher in the study group when compared to the placebo control group 
(30.60 ± 7.789 vs 8.87 ± 7.248). Similarly, better mean reduction in the 
psychological (19.43 ± 8.96 vs 4.23 ± 5.49) and behavioural (19.30 ± 7.3 vs 
3.33 vs 4.097) scores was observed in the study group in comparison to the 
control group (Table 2).   
The results are also expressed in terms of median due to a wider range and 
standard deviation observed, especially in the control group. A statistically 
significant reduction in all three physiological, psychological and behavioural 
scores (p<0.0001) was observed in the intervention group when compared to 
the control group (Table 3). Interestingly, within group analysis showed a 
statistically significant reduction in the control group similar to that of the 
intervention group (both p<0.001). However, the difference in reduction in the 
control group was not as ‘clinically’ significant or relevant as in the 
intervention group in the physiological (7.50 vs 32.50), psychological (6.0 vs 
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19.50) and behavioural (2.50 vs 20.0) scores. Therefore, the results shows a 
high level of statistical and clinical significance and highly favours the 
intervention group in the reduction of all 3 components of the PMSS when 
compared to the placebo-controlled group. 
 
 
Table 1:  Summary of Study characteristics (n=60) 
 
 
Physiologi
cal  
Pre score 
Physiologic
al 
Post score 
Physiologic
al 
Difference 
score 
Psychologi
cal  
Pre score 
Psychologi
cal 
Post score 
Psycholo
gical 
Differenc
e score 
Behaviour
al 
Pre score 
Behaviour
al 
Post score 
Behavio
ural 
Differen
ce score 
N 60 60 60 60 60 60 60 60 60 
Mean 65.07 45.33 19.73 51.22 39.38 11.83 51.50 40.18 11.32 
Media
n 
65.50 45.00 21.00 51.50 42.50 10.00 52.00 38.50 7.50 
SD 7.346 16.628 13.256 5.149 10.235 10.633 5.500 9.663 9.963 
Minim
um 
50 21 0 41 21 -5 41 22 0 
Maxim
um 
80 72 44 60 56 36 60 59 32 
IQR (61.00 , 
69.00) 
(28.25 , 
61.00) 
(8.00 , 
30.75) 
(48.00 , 
55.75) 
(31.25 , 
46.00) 
(3.00 , 
21.00) 
(47.25 ,  
56.00) 
(32.00 , 
50.00) 
(2.00 , 
20.00) 
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Table 2: Summary of study characteristics by group 
 
Group 
Physiolog
ical  
     Pre 
score 
Physiolo
gical 
Post 
score 
Physiol
ogical 
Differen
ce score 
Psycholo
gical  
Pre score 
Psycholo
gical 
Post 
score 
Psycholo
gical 
Differenc
e score 
Behaviou
ral 
Pre score 
Behaviou
ral 
Post 
score 
Behaviou
ral 
Differenc
e score 
Cont
rol  
N 30 30 30 30 30 30 30 30 30 
Mean 69.77 60.90 8.87 52.07 47.83 4.23 51.83 48.50 3.33 
Media
n 
68.50 61.00 8.00 52.00 46.00 3.50 52.50 50.00 2.00 
SD 5.488 5.215 7.248 4.417 4.450 5.494 5.427 5.859 4.097 
Mini
mum 
61 51 0 43 44 -5 41 39 0 
Maxi
mum 
80 72 27 60 56 16 60 59 20 
IQR (65.75 , 
74.25) 
(56.75 , 
64.25) 
(2.75 , 
12.00) 
(48.75 , 
56.00) 
(44.75 , 
54.00) 
(-.25 , 
8.00) 
(47.75 , 
56.25) 
(41.75 , 
53.00) 
(1.00 , 
4.00) 
Stud
y  
N 30 30 30 30 30 30 30 30 30 
Mean 60.37 29.77 30.60 50.37 30.93 19.43 51.17 31.87 19.30 
Media
n 
61.00 28.50 30.50 51.00 31.50 21.00 52.00 32.00 19.50 
SD 5.828 5.829 7.789 5.738 6.751 8.962 5.645 3.540 7.302 
Mini
mum 
50 21 14 41 21 3 41 22 3 
Maxi
mum 
70 39 44 60 41 36 60 38 32 
IQR (55.75 , 
65.25) 
(24.75 , 
35.25) 
23.75 , 
37.00) 
(45.00 , 
55.25) 
(23.75 , 
37.00) 
(12.00 , 
26.25) 
(46.75 , 
55.25) 
(29.75 , 
35.00) 
(14.75 , 
24.00) 
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Figure 3: Histogram of Physiological symptom score difference 
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 Figure 4: Histogram of Psychological symptom score difference 
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Figure 5: Histogram of Behavioural symptom score difference 
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Table 3: Comparison on Physiological, Psychological and Behavioural symptom 
score between groups using Mann Whitney test 
 
 
 Control Group Study group  
P value N Median(IQR) N Median(IQR) 
Physiological Pre score 30 68.50 (65.75 , 74.25) 30 61.00 (55.75 , 65.25) - 
Physiological Post score 30 61.00 (56.75 , 64.25) 30 29.77  (24.75 , 35.25) - 
Physiological Difference 
score 
30 08.00 (2.75 , 12.00) 30 30.50 (23.75 , 37.00) <0.0001 
Psychological Pre score 30 52.00 (48.75 , 56.00) 30 50.37 (45.00 , 55.25) - 
Psychological Post score 30 46.00 (44.75 , 54.00) 30 31.50 (23.75 , 37.00) - 
Psychological Difference 
score 
30 03.50 (-0.25 , 8.00) 30 21.00 (12.00 , 26.25) <0.0001 
Behavioural Pre score 30 52.50 (47.75 , 56.25) 30 52.00 (46.75 , 55.25) - 
Behavioural Post score 30 50.00 (41.75 , 53.00) 30 32.00 (29.75 , 35.00) - 
Behavioural Difference 
score 
30 02.00 (1.00 , 4.00) 30 19.50 (14.75 , 24.00) <0.0001 
 
 
Interpretation: There is an evidence to show that statistically significant (all 3 
parameters change p = <0.0001) difference between groups on their change of 
Physiological, Psychological and Behavioural symptom score.  
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Table 4:  Analysis of with in group comparison using Wilcoxon signed Rank test 
 
 
Group 
Physiolog
ical  
     Pre 
score 
Physiolo
gical 
Post 
score 
Physiol
ogical 
Differen
ce score 
Psycholo
gical  
Pre score 
Psycholo
gical 
Post 
score 
Psycholo
gical 
Differenc
e score 
Behaviou
ral 
Pre score 
Behaviou
ral 
Post 
score 
Behavio
ural 
Differen
ce score 
Cont
rol  
N 30 30 30 30 30 30 30 30 30 
Media
n 
68.50 61.00 7.50 52.00 46.00 6.00 52.50 50.00 2.50 
IQR (65.75 , 
74.25) 
(56.75 , 
64.25) 
(2.75 , 
12.00) 
(48.75 , 
56.00) 
(44.75 , 
54.00) 
(-.25 , 
8.00) 
(47.75 , 
56.25) 
(41.75 , 
53.00) 
(1.00 , 
4.00) 
P 
value 
- - <0.0001 - - 0.001 - - <0.0001 
Stud
y  
N 30 30 30 30 30 30 30 30 30 
Media
n 
61.00 28.50 32.50 51.00 31.50 19.50 52.00 32.00 20.00 
IQR (55.75 , 
65.25) 
(24.75 , 
35.25) 
23.75 , 
37.00) 
(45.00 , 
55.25) 
(23.75 , 
37.00) 
(12.00 , 
26.25) 
(46.75 , 
55.25) 
(29.75 , 
35.00) 
(14.75 , 
24.00) 
P 
value 
- - <0.0001 - - <0.0001 - - <0.0001 
 
 
 
 
Interpretation: There is an evidence to show that statistically significant difference 
between pre and post of Physiological, Psychological and Behavioural symptom 
score in the study group (p = <0.0001). Also the same significant difference observed 
in the control group. 
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6. DISCUSSION 
Comparisons between groups was measured using Mann whitney U-test 
and within group was measured using Wilcoxon signed rank test. In this study, 
the severity of PMS physical and mental symptoms in all participants who had 
received thirty six sessions of intervention had a significant reduction 
compared to the Placebo-control group; however, the reduction was higher in 
the aroma exposure group than in the Placebo-control group. Reviewing 
articles showed many studies on aromatherapy, but very little research has been 
done on aromatherapy nasal exposure particularly its effects on PMS. Lavender 
oil research investigated the effects of aromatherapy on PMS emotional 
symptoms, and their study showed that aromatherapy inhalation reduced PMS 
emotional symptoms [129]. The book “Ayurveda and Aromatherapy” mentions 
that “Clary sage has a rejuvenating effect on the endocrine system. It balances 
the pituitary and is especially effective at feeding estrogen directly into the 
skin.” [100]. In this case we have studied the effects of clary sage oil through 
nasal exposure and its effects on physiological, psychological and behavioural 
symptoms. This study also showed that the severity of physiological symptoms 
such as breast tenderness and swelling, abdominal bloating, weight gain, 
headache, dizziness/fainting, fatigue, palpitation, pelvic discomfort and pain, 
abdominal cramps, change in bowel habits, increased appetite, generalized 
aches and pain, food craving(sugar/salt), skin changes, rashes and pimples, 
nausea/vomiting, muscle and joint pain; psychological symptoms such as 
irritability, anxiety, tension, mood swings, loss of concentration, depression, 
forgetfulness, easy crying/crying spells, sleep changes, insomnia/hypersomnia, 
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confusion, aggression, hopelessness; behavioural symptoms such as social 
withdrawal, restlessness, lack of self-control, feeling guilty, clumpsiness, lack 
of interest in usual activities, poor judgement, impaired work performance, 
obsessional thoughts, compulsive behavior, irrational thoughts, being over-
sensitive decreased more in the study group than in the placebo-control group. 
Since this research is the first study involving clary sage oil in the field of 
aromatherapy on PMS, in that case positive results have been obtained, hence 
further studies are recommended to confirm the findings. 
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7. CONCLUSION 
The present study indicated Clary sage aromatherapy as a potential 
therapeutic modality, is attributable to the improvement of physiological, 
psychological and behavioural symptoms. This study further implies that Clary 
sage helps to relieve premenstrual symptoms, and ultimately, support the mind 
and body health of women. 
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 9. ANNEXURES 
    INFORMATION SHEET 
We are conducting a study “Efficacy of Clary sage oil on Pre-Menstrual Syndrome 
(PMS) – A Controlled Trial” at Government Yoga and Naturopathy Medical College 
Hospital, Chennai – 106. 
The purpose of this study is to evaluate the efficacy of aromatherapy in relieving the 
symptoms of premenstrual syndrome. 
We need your participation in this study. There is no invasive investigation for the study. 
The privacy of the patients in the research will be maintained throughout the study. In the 
event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to participate in this 
study or to withdraw at any time; your decision will not result in any loss of benefit to 
which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the study period or 
during the study if anything is found abnormal which may aid in the management or 
treatment. 
Signature of investigator:                                                    
Signature of participant: 
Date: 
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INFORMED CONSENT FORM 
Title of the study: 
“Efficacy of Clary sage oil on Pre-Menstrual Syndrome (PMS) – A Controlled Trial” 
Name of the Participant:  
Name of the Principal Investigator:  Dr. Geethanjali.S 
Name of the Institution: Government Yoga & Naturopathy Medical College, 
Chennai – 600 106. 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it has been 
read to me). I was free to ask any questions and they have been answered. I am over 18 
years of age and, exercising my free power of choice, hereby give my consent to be 
included as a participant in “Efficacy of Clary sage oil on Pre-Menstrual Syndrome 
(PMS) – A Controlled Trial” 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have taken in 
the past ________ months including any native (alternative) treatment. 
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6. I have been advised about the risks associated with my participation in this study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately if I 
suffer unusual symptoms.  
8. I have not participated in any research study within the past _________month(s).  
9. I am aware of the fact that I can opt out of the study at any time without having to give 
any reason and this will not affect my future treatment in this hospital.  
10. I am also aware that the investigator may terminate my participation in the study at any 
time, for any reason, without my consent.  
12. I hereby give permission to the investigators to release the information obtained from 
me as result of participation in this study to the sponsors, regulatory authorities, Govt. 
agencies, and IEC. I understand that they are publicly presented. 
13. I have understood that my identity will be kept confidential if my data are publicly 
presented. 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the investigator. 
By signing this consent form I attest that the information given in this document has been 
clearly explained to me and understood by me, I will be given a copy of this consent 
document. 
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Name and signature / thumb impression of the participant  
 
Name _________________________ Signature_________________  
 
Date________________ 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name _________________________ Signature_________________  
 
Date________________ 
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 INFORMATION TO PARTICIPANTS 
Investigator: Dr. Geethanjlali. S 
Name of Participant: 
Title:  
“Efficacy of Clary sage oil on Pre-Menstrual Syndrome (PMS) – A Controlled Trial” 
You are invited to take part in this research/ study /procedures. The information in this 
document is meant to help you decide whether or not to take part. Please feel free to ask if 
you have any queries or concerns. You are being asked to participate in this study being 
conducted in Government Yoga & Naturopathy Medical College, Chennai – 600 106 
What is the Purpose of the Research? 
The purpose of this study is to evaluate the efficacy of aromatherapy in relieving the 
symptoms of Pre-menstrual syndrome 
The Study Design: 
60 patients are exposed to clary sage oil inhalation through diffuser. 
Study Procedures: 
Patients are initially screened to rule out depression and Pre-menstrual Dysphoric disorder 
with questionnaires before and at the end of intervention. They will be asked to maintain a 
symptoms diary to throughout the study. 
Possible Risks to you : nil 
112 
 
Possible benefits to you:  
Aromatherapy exposure helps you in coping up with the Pre-menstrual symptoms you 
experience every month. 
Possible benefits to other people: 
The result of the research may provide benefits to the society in terms of advancement of 
medical knowledge and/or therapeutic benefits to future patients.  
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical information 
(personal details, results of physical examinations, investigations, and your medical 
history). By signing this document, you will be allowing the research team investigators, 
other study personnel, sponsors, IEC and any person or agency required by law like the 
Drug Controller General of India to view your data, if required. 
The information from this study, if published in scientific journals or presented at scientific 
meetings, will not reveal your identity. 
How will your decision to not participate in the study affect you? 
Your decisions to not to participate in this research study will not affect your medical care 
or your relationship with investigator or the institution. Your doctor will still take care of 
you and you will not lose any benefits to which you are entitled. 
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Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to withdraw 
from this study at any time during course of the study without giving any reasons. However, 
it is advisable that you talk to the research team prior to stopping the treatment. 
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REMARKS OF THE GUIDE 
 
 
This work undertaken / to be done by Dr. Geethanjali. S titled “Efficacy of Clary sage oil 
on Pre-Menstrual Syndrome (PMS) – A Controlled Trial” at Government Yoga and 
Naturopathy Medical College Hospital, will be under my supervision and I ensure that the 
candidate will abide by the rules of the Institutional Ethics Committee. 
 
 
 
Dr. N. Mangaiarkarasi B.N.Y.S, M.Sc. (psy), PGDHAN, 
H.O.D 
 Dept. of Acupuncture And Energy Medicine, 
Government Yoga and Naturopathy Medical College, Chennai– 600106 
Date: 
 
 
 
 
 
 
115 
 
The premenstrual symptoms screening tool (PSST) 
(please mark an “X” in the appropriate box) 
Do you experience some or any of the following premenstrual symptoms which start before your period and 
stop within a few days of bleeding? 
 
Symptom Not at all Mild Moderate Severe 
1.Anger / irritability     
2. Anxiety / tension     
3.Tearful/Increased sensitivity to rejection     
4.Depressed mood/hopelessness     
5.Decreased interest in work activities     
6. Decreased interest in home activities     
7. Decreased interest in social activities     
8.Difficulty concentrating     
9.Fatigue / lack of energy     
10.Overeating / food cravings     
11.Insomnia     
12.Hypersomnia (needing more sleep)     
13.Feeling overwhelmed or out of control     
14.Physical symptoms: breast tenderness, headaches, 
joint/muscle pain, bloating, weight gain 
    
Have your symptoms, as listed above, interfered with: 
 
 Not at all Mild Moderate Severe 
A. Your work efficiency or productivity     
B. Your relationship with co-workers     
C. Your relationships with your family     
D. Your social life activities     
E. Your home responsibilities     
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Scoring 
The following criteria must be present for a diagnosis of PMDD 
1. At least one #1, #2, #3, #4 is severe 
2. In addition at least four of #1 to #14 are moderate to severe 
3. At least one of A, B, C, D, E is severe 
 
The following criteria must be present for a diagnosis of moderate to severe PMS 
1. At least one #1, #2, #3, #4 is moderate to severe 
2. In addition at least four of #1 to #14 are moderate to severe 
3. At least one of A, B, C, D, E is moderate to severe 
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                                               PREMENSTRUAL SYNDROME SCALE 
   SCORES  
 
 
Physiological symptoms 
1 Breast tenderness and swelling 
2 Abdominal bloating 
3 weight gain 
4 Headache 
5 Dizziness/fainting. 
6 Fatigue 
7 Palpitations 
8 Pelvic discomfort and pain 
9 Abdominal cramps 
10 Change in bowel habits 
11 Increased appetite 
12 Generalized aches and pains 
13 Food cravings (Sugar/ Salt) 
14 Skin changes, rashes, pimples 
15 Nausea/vomiting 
16 Muscle and Joint pain 
Psychological symptoms 
17 Irritability 
18 Anxiety 
19 Tension 
20 Mood swings 
21 Loss of concentration 
22 Depression 
23 Forgetfulness 
24 Easy crying/ Crying spells 
25 Sleep changes (Insomnia/ hypersomnia) 
26 Confusion 
27 Aggression 
28 Hopelessness 
Behavioural symptoms 
29 Social withdrawal 
30 Restlessness 
31 Lack of self control 
32 Feeling guilty 
33 Clumsiness 
34 Lack of interest in usual activities 
35 Poor judgment 
36 Impaired work performance 
37 Obsessional thoughts 
38 Compulsive behavior 
39 Irrational thoughts 
40 Being over sensitive 
 
 
Never 
(1) 
Rarely 
(2) 
Sometimes 
(3) 
Very often 
(4) 
Always 
(5) 
In       
addition, the total score obtained from the sub-scales established the “PMSS total score.” The scale’s lowest 
score is 40 and highest score is 200. If the scale’s total score reached 80 points or above, this indicates the 
occurrence of PMS. Increases in the scores indicate an increase in PMS severity. 
 
SCORING PROCEDURE: 
Based on the percentage of scores the levels of premenstrual symptoms were graded in four categories. They are 
“No symptoms”, “Mild”, “Moderate” “severe” and very severe symptoms. 
 
Level of symptoms  Actual Scores Percentage of Scores 
No symptoms  1- 40 < 20 
Mild symptoms - only slightly apparent 41 - 80 21 -40 
Moderate symptoms - aware of symptom, but it doesn’t affect daily activity at all 81 – 120 41 60 
Severe - continuously bothered by symptoms 121 - 160 61 -80 
very severe - symptom is overwhelming and /or interferes with daily activity 161 -200 > 80 
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